Abstract Presentation Schedule

Both the Scientific and Living with Parkinson's abstracts will be displayed in the exhibit hall. Authors are required to represent and discuss their work on one day over the lunch hour. The schedule below shows you which posters will show on which day.

All authors have been notified of the final decision as well as the presentation schedule below. If you submitted and abstracts and have not recieved an email with these details, please immediately contact the WPC Abstract Coordinator at abstracts@worldpdcongress.org or by calling: +44 141 3310123.


Wednesday, September 29 from 12:30 - 14:30
Scientific Abstracts | Late Breaking | Living with Parkinson's

Thursday, September 30 from 11:30 - 13:30
Scientific Abstracts | Late Breaking | Living with Parkinson's

Friday, October 1 from 12:45 - 14:25
Scientific Abstracts | Late Breaking | Living with Parkinson's

---

WEDNESDAY - Scientific Abstracts

Basic Science: Etiology, Genetics, Epidemiology and Toxicants
P01.01 Alcohol Consumption and Risk of Parkinson Disease in a Large Prospective Cohort of Men and Women: N Palacios , X Gao, E O'Reilly, M Schwarzschild, M McCullough, S Gapstur, T Mayo, A Ascherio
P01.02 Prevalence of Mutations in Parkin, PINK1 and DJ-1 in Early Onset Parkinson's Disease – A Community Based and Regional Study: J Pearson , L Kilarski, V Newsway, E Majounie, D Perera, A Misbahuddin, P Chinnery, D Burn, A Lewthwaite, C Clarke, K Morrison, J Evans, S Sawcer, R Barker, M Wickremaratchi, N Williams, H Morris
P01.03 Outdoor work and risk for Parkinson disease: a population–based case–control study: L Kenborg , C Lassen, B Ritz, E Schernhammer, J Hansen, N Gatto, J Olsen
P01.04 Risk for Parkinson disease among patients with osteoarthritis: a Danish cohort study: K Rugbjerg , S Friis, T Jørgensen, B Ritz, L Korbo, J Olsen
P01.05 Molecular Genetic Spectrum in Korean Patients with Early-onset Parkinson Disease: B Jeon, S Kim, H Kim , S Kim, H Ko, J Kim, S Park
P01.06 A Splice Isoform Signature Of Parkinson's Disease In Blood: J Potashkin , C Scherzer, B Ravina, A Watts, A Leontovich
P01.07 Characterization of Autophosphorylation in the Leucine-rich Repeat Kinase 2 (LRRK2) GTPase Domain: A West , P Webber, A Smith, S Sen, S Biskup, Z Yue, J Mobley, B Horton
P01.08 Proteomic Analysis of the Locus Ceruleus in Parkinson's Disease : K van Dijk , S Fratantoni, T Pham, S Piersma, H Groenewegen, H Berendse, C Jimenez, W van de Berg 
P01.09 High Dose Human Paraquat Exposures and the Subsequent Development of Parkinsonism : J Brent
P01.27 ATP13A2 Variants Contribute to the Risk for Parkinson Disease in Taiwan: C Chen , Y Wu, G Lee-Chen
P01.28 A Case Control Study of Multiple System Atrophy in Korean patients: J Kim, J Lee , P Lee
P01.29 Early Mortality in An Incident Cohort of People with Parkinson's Disease and Parkinsonism.: R Caslake , N Scott, C Harris, J Gordon, C Counsell

Basic Science: Cell Death Mechanisms, Neuroprotection and Trophic Factors
P02.01 The journey from mice to men: The Role of T cells in the immunobiology of Parkinson's disease.: J Saunders , D Stone, A Reynolds, L Kosloski, D Standaert, R Mosley, H Gendelman
P02.02 DJ-1 Neuroprotection in Parkinson's Disease: Effects of Cysteine Oxidation and Subcellular Localization : J Rochet , F Liu, K Lesniak, V Mishra, J Travers
P02.03 LUHMES Cells as Human In Vitro Model to Study Mechanisms of Parkinsonian Neurodegeneration: D Pöltl , S Schildknecht, M Leist
P02.04 HIF Prolyl Hydroxylase Inhibition Increases Cell Viability And Potentiates Dopamine Release In Dopaminergic Cells: K Thirstrup , J Johansen, T Sager, A Mørk, A Bergström, J Egebjerg
P02.05 Phosphorylation of Parkin by the c-Abl Protein Tyrosine Kinase Inhibits parkin¡¯s Ubiquitination and Protective Function.: H Ko , Y Lee, J Shin, S Karuppagounder, B Gadad, A Koleske, O Pletinkova, J Troncoso, V Dawson, T Dawson
P02.17 Regulation of Neuronal Survival Factor MEF2D by Chaperone-mediated Autophagy : Q Yang, H She, M Gearing, E Colla, M Lee, J Shacka, Z Mao
P02.18 Effect of R-apomorphine on Gene Expression of Neurotrophins & Inflammatory Markers in the Striatal 6-Hydroxydopamine Rat Model of Parkinson's Disease: M Varcin , B Mertens, R Kooijman, Y Michotte, S Sarre

Basic Science: Protein Misfolding and Handling
P03.01 Unraveling The Role Of Peptidyl-Prolyl Isomerases In The Aggregation Of Alpha-Synuclein: A Deleersnijder, M Gérard, Z Debyser, V Baekelandt
P03.02 Effects of Membrane Binding and Post-Translational Modifications on Alpha-Synuclein Toxicity in Parkinson's Disease: J Rochet , K Strathearn, A Griggs, J Hindupur, J Schieler, K Head
P03.06 Modeling LRRK2 function with LRRK1: L Patrick

Basic Science: Mitochondria, Oxidative Stress, Inflammation and Other Pathogeneses  
P04.03 An Ill-Fated Substantia Nigra Through The Systems Looking Glass An Energetic Overview: F Francis , M Garcia, P Wellstead, R Middleton
P04.04 Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model: N Stefanova , H Eriksson, B Georgievska, W Poewe, G Wenning
P04.05 Fcy Receptors are Required for NF-kappaB signaling, Microglial Activation and Dopaminergic Neurodegeneration in an AAV a-synuclein Mouse Model of PD: D Standaert , S Cao, S Theodore
P04.17 Levels of Reduced and Oxidized CoenzymeQ-10 and 8-hydroxy-2-Deoxyguanosine in the Cerebrospinal Fluid of Patients with Living Parkinson's Disease: C Isobe , T Abe, N Hattori, Y Terayama
P04.18 Effect Of Caffeine And Selective Adenosine A1 and A2A Antagonists On MDMA Induced Dopaminergic Neurotoxicity In Mouse Brain: A Khairnar , L Frau, A Plumitallo, S Fenu, M Morelli

Basic Science: Pathology
P05.01 Pathologic Considerations of the Pedunculopontine Nucleus and Locus Coeruleus in Rapid Eye Movement Behavior Disorder: B Dugger , M Murray, B Boeve, E Benarroch, T Ferman, D Dickson  
P05.02 Does Levodopa Affect Progression of Neuropathology in Parkinson's Disease? A Clinico-Pathological Study: L Parkkinen, S O'Sullivan, M Kuoppamäki, C Collins, C Kallis, J Holton, T Revesz, A Lees

Basic Science: Animal and Cellular Models  
P06.06 LRRK2, a Gene Mutated in Parkinson's Disease, Promotes Synaptic Vesicle Endocytosis: S Matta , V Morais, W Mandemakers, S Vilain, B De Strooper, P Verstreken
P06.07 Study On Functional Redundancy Of LRRK1 And LRRK2 : W Mandemakers , S Matta, V Morais, A Snellinx, B De Strooper
P06.08 Modeling Parkinson's Disease In Adh1 And Adh1/4 Knockout Mice: A Anvret , C Ran, M Westerlund, E Lindqvist, K Pernold, K Lundströmer, G Duester, M Felder, D Galter, A Carmine Belin
P06.09 A Rat Lipopolysaccharide Model for Parkinson's disease Neurodegeneration: Inflammatory cells and Cytokines in Brain Tissue : R Bick , M Schurdell, L Young, U Osuagwu, B Poindexter, M Doursout, D Bick, T Ellmore, M Schiess
P06.10 Predominant Expression of Mutant A30P alpha-Synuclein in Olfactory Bulb of a Conditional Mouse Model: Implications for Early Stage of Parkinson's Disease: S Nuber , E Petrasch-Parwez, O Arias-Carrion, H Nguyen, S von Hoersten, P Teismann, J Schulz, T Velavan, M Fendt, T Schmidt, Z Kohl, J Boy, K Fischer, C Calaminus, G Hoeglinger, J Winkler, B Pichler, O Riess
P06.17 Neuroprotective Effect of Human Mesenchymal Stem Cells in an Animal Model of Double-toxin-induced Multiple System Atrophy-parkinsonism: P Lee , J Lee, J Kim, H Park
P06.18 Overexpression of a-Synuclein Alters Dopamine Neurotransmission In Vivo Before Onset of Behavioral Deficits and Dopaminergic Cell Loss in Rats: M Lundblad , M Decressac, A Björklund

Basic Science: Brain Physiology and Circuitry
P07.01 Chronic Effect Of The Dopamine D3 Receptor Agonist And BDNF On The Motor Deficit In The Rat Model Of Parkinson's Disease: L Razgado-Hernandez , A Sierra, D Martinez-Fong, I Jimenez, V Anaya, J Aceves

Basic Science: Dopamine, Receptors and Other Neurotransmitters
P08.01 Therapeutic potential of caffeine derivate 1-methylxanthine, as A2A adenosine receptor antagonist on striatopallidal pathway: L Jimenez-Botello , M Ávila-Costa, J Carillo-Ruiz, J Correa-Basurto, O Picazo, E Querejeta-Villagomez

Basic Science: Neuropharmacology
P10.01 Antioxidative potential of quercetin analogues against MPP+ toxicity in dopaminergic cells: W Rausch , C Ma, I Wichart, R Moldzio, P Riederer, Y Yan
P10.02 PYM50028 (Cogane™), An Orally Active Neurotrophic Factor Modulator Enhances The Effect Of L-DOPA In MPTP-Lesioned Macaques.: T Johnston, J Koprich, S Fox, C Ward, R Hickling, P Howson , J Brotchie
P10.05 Topiramat in treatment of Essential Tremor©: Z Zalyalova
P10.06 Changes in Extracellular Noradrenalin Levels After L-DOPA Administration In The Normal Rat Striatum And Cerebral Cortex: K Kannari , E Ishizawa

Basic Science: Electrophysiology  
P11.01 Evaluation of Sex and Stage Progression of Parkinson's Disease During Functional Tasks: K Roland , G Jones, J Jakobi
P11.06 Reflexive And Voluntary Saccades In Patients With Parkinson's Disease: R Bogdanov , L Turbina, A Litvinova, P Ratmanova, D Napalkov
P11.07 Quantitative Estimation of Parkinson Patients EEG Wavelet Spectrograms Disorganization.: M Korolev , A Gabova

Clinical Science: Symptoms, Signs, Clinical Features and Progression  
P13.01 Isometric Quickness Protocol as an Objective Assessment of Bradykinesia in Parkinson's disease. : I Pretzer-Aboff , C Knight
P13.02 Are results from PD trials generalizable? The NPF database reveals a mismatch between typical clinic populations and subjects in PD trials.: P Schmidt , M Okun, A Siderowf, J Nutt, G O'Conner, B Bloem, E Olmstead, M Guttman, T Simuni, E Cheng, S Parashos, L Marsh, I Malaty, N Giladi, S Wu, J Oberdorf  
P13.03 Objective Measures of Parkinson's Disease Functional Motor Impairment with Finger and Toe Tapping: J McNames , F Kernan, L Holmstrom, M Aboy, B Casady, E Katz, J Boureen, F Horak, J Nutt
P13.04 A clinicopathological study of a case of Parkin disease : K Doherty , L Silveira-Moriyama, Z Ahmed, T Revesz, J Holton, A Lees 
P13.05 Pisa syndrome (PS) and striatal hand in Parkinson`s disease patient: S Pandey , M Mehndiratta
P13.06 Clinic based videotaped assessment of turning patterns in Parkinson's disease: M Jog , A Salmon, H Kumar, A South
P13.07 Bradykinesia in Parkinson's Disease and Related Conditions: H Ling , L Massey, A Lees, P Brown, P Schwingenschuh, K Bhatia, B Day
P13.08 Camptocormia Due to Neuro-oncologic Lumbar Spine Surgery with Instrumentation Technique in a non Parkinsonian Patient.: I Casas Parera , J Igirio Gamero, J Tafur Canabal, A Baez, M Baez, J Cardozo Oliver
P13.09 Identification of Physical, Cognitive, and Affective Variables that Relate to Falls in Parkinson's Disease: L Elmer , J Wilhelm, M Masterson
P13.10 Early Use of Amantadine May Postpone Levodopa-Induced Dyskinesia and Cognitive Impairment in Patients with Parkinson's Disease: T Yates , T Ward, G Lennox 
P13.11 Switching Directions of the Eyes and Leg: Relationship to Freezing in Parkinson Disease: C Lohnes , G Earhart
P13.12 Bedside Clinical Evaluation Of Ocular Features In Atypical Parkinsonian Syndromes: R Nehru, A Batla, T Vijay , J Sharma
P13.13 Detection and Quantification of Freezing of Gait Using a Repetitive Stepping in Place Task: J Nantel , C de Solages, H Bronte-Stewart
P13.39 Hemiparkinsonism And Bilateral Blepharoclonus Due To A Mesencephalic-Subthalamic Nucleus Cavernoma: A Case Report: C Singer, H Moore, R Heros
P13.38 Parkinson's disease or Parkinson's complex: Cardinal Motor Signs Dissociations Figures and Parkinson's District Clinics / Sections: S Echebarria Mendieta
P13.40 Postural Instability and Cognitive Dysfunction in Patients with Early-Stage Parkinson's Disease: A Computerized Dynamic Posturographic Study: S Koh, J Lee, S Chae, H Shin

Clinical Science: Non-motor Features
P14.01 Prospective study of bowel movement frequency and Parkinson disease risk: X Gao, H Chen, M Schwarzschild, A Ascherio
P14.02 Tolerability Of Apomorphine Infusion In Advanced Parkinson's Patients With Hallucinations And Gastrointestinal Symptoms: Implications For Treatment: C Chandiramani , P Reddy, A Martin, K Chaudhuri, M Canesi, P Martinez-Martin, A Antonini, A Todorova, P Odin, T Henriksen, C Falup-Pecurariu, C Falup-Pecurariu, C Falup-Pecurariu, D Brooks, Y Naidu, S Tluk, C Trenkwalder, D Aarsland, J Van Hilten, G MacPhee 
P14.03 A Virtual Arena Test Indicates Deficient Striatal Spatial Memory Strategies in Mild Parkinson's Disease: T Gudmundsdottir, C Doeller, N Burgess, F Bergquist  
P14.04 L-Dopa/Carbidopa Gel Dose-Response Relationships With Cognitive, Emotional And Motor Features In Patients With Advanced Parkinson's Disease: T Nissen , H Honig, A Rüssmann, K Fox, R Brown, P Odin
P14.05 Measuring quality of life in patients with Parkinson's Disease using the McGill Quality of Life questionnaire: M Jog , T Gofton, H Kumar, A South, M Speechly
P14.20 Lower Basal Leg Vascular Tone and Larger Plasma Volume in Parkinson's Disease Patients with Orthostatic Hypotension: J Groothuis, R Esselink, J Seeger, B Bloem , M Hopman
P14.21 Measuring Perception of Subjective Visual Vertical using the Computerised Rod and Frame Test in Parkinson's Disease Patients: K Amar , S Docherty, J Bagust, R Wellington, A Khattab

Clinical Science: Biomarkers and Neuroimaging  
P15.01 Abnormalities of White Matter Architecture and Connectivity in Parkinsonian Gait Freezing: Implications for Treatment: P Schweder, A Green, P Hansen, J Stein, T Aziz
P15.02 A Structural Morphometric Imaging Analysis of the Brainstem and Cerebellum in a DBS Cohort of Parkinson's Disease: P Schweder, C Joint, P Hansen, G Quaghebeur, A Green, T Aziz
P15.03 F-18 FDG-PET is a useful tool in clinical practice for diagnosing corticobasal ganglionic degeneration: M Tripathi, R Nehru, A Batla, R Sharma, A Mondal, T Vijay
P15.04 Serotonergic involvement in L-DOPA-induced dyskinesia: M Politis, K Wu, C Loane, L Kiferle, S Molloy, P Bain, D Brooks, P Piccini
P15.05 Significance of Hand Tremorography and Symmetrical Sensorimotor Coordinometry in Patients with Parkinson's Disease: M Gospodinov
P15.06 The PARS study: Identifyng pre-diagnostic parkinsonian features in a healthy hyposmic cohort: D Jennings, A Siderowf, M Stern, K Marek, PARS Study Investigators
P15.24 Association between High-Sensitivity C-Reactive Protein and Risk of Early Idiopathic Parkinson's Disease: K Lee, I Song, J Kim, S Chung, H Kim
P15.25 Hematopoiesis: A Biomarker for Neurodegeneration: S Biskup, N Funk, R Schäfer, T Gasser
P15.26 Clinical Correlation of Neuroimaging in Diagnosis of Extra Pyramidal Disorders: S Kushwaha, P Singh, S Sharma

Clinical Science: Medical Therapy
P16.01 Side-effects and withdrawal rates for oral non-ergot dopamine agonists used as monotherapy in routine clinical practice: S King, E Newman , K Grosset, G Macphee, D Grosset
P16.02 ITI-007: A Novel Treatment for Sleep Disorders and Dyskinesia in Parkinson's Disease : K Vanover , R Davis, G Snyder, J Hendrick, G Fisone, A Fienberg, L Wennogle, S Mates
P16.03 Development of Novel PDE1 Inhibitors as Dose-Sparing Medications in Parkinson's Disease: G Snyder , K Vanover, H Zhu, L Zhang, P Li, J Hendrick, G Fisone, R Davis, A Fienberg, L Wennogle, S Mates
P16.04 Patient Perspectives Towards Levodopa Therapy in Japan and the United States – Results of Two Patient Surveys: K Fujimoto, N Hattori , T Kondo, M Murata, M Stacy
P16.05 Drug Treatment Characteristics for People with Parkinson's in United Kingdom.: G Drutyte , K Breen
P16.06 Novel metal ligands prevent neuronal loss and motor deficits in wild type and alpha-synuclein transgenic mice treated with 6-hydroxydopamine or MPTP.: R Cherny , J George, L Gunawan, N Critch, M Cortes, X Liu, M Nurjono, K Laughton, I Volitakis, J Parsons, K Barnham, E Gautier, A Bush, D Finkelstein

Clinical Science: Surgical Therapy
P17.01 Urological Interventions in Parkinson's disease:The Kokilaben Hospital experience: P Sanjay , M Bhatt
P17.02 Deep Brain Stimulation Alters Subthalamic Nucleus Connectivity: Neuroimaging Evidence: P Schweder , C Joint, A Green, G Quaghebeur, T Aziz
P17.03 Subthalamic Nucleus Functional Connectivity in Parkinson's Disease: P Schweder , C Joint, G Quaghebeur, A Green, T Aziz
P17.09 Application Of The STIMULUS Screening Tool In The Pre-Selection For Deep Brain Stimulation In Patients With Parkinson´S Disease: F Lena, C Rossi, S Brotini , G Bianco, C Battisti, N Modugno, R Ceravolo, S Rossi, D Maffei, H Stoevelaar
P17.10 Relationship Between the Decline in Verbal Fluency and Deep Brain Stimulation of the Subthalamic Nucleus: a Case Report: G Tommasi , J Yelnik, L Bertolasi, F Sala, G Ricciardi, E Bardinet, E Fincati, A Fiaschi

Clinical Science: Complications of Therapy
P18.01 Entacapone adverse effects in clinical practice.: C Wai Ho, E Newman , K Grosset, G Macphee, D Grosset
P18.04 Plasma Homocysteine Levels Increased Risk of Levodopa-Induced Dyskinesia in Parkinson's Disease : J.J. Lin, K.Y.Yueh
P18.05 A Study on the Prevalence and Predictors of Levodopa Induced Dyskinesias in Parkinson's Disease: M Norlinah, Z Hasnur, W W NurNafisah, H Tan, A Raymond

Clinical Science: Clinical Trials
P19.01 Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in PD: J Friedman, B Ravina, R Mills, H Williams , D Bahr, P Peters, F Tison, D Burn
P19.02 Interim Analysis of an Open-Label Extension Study to Examine the Long-Term Safety and Tolerability of Pimavanserin in the Treatment of PD Psychosis. : R Mills , D Bahr, H Williams, P Peters, S Isaacson
P19.03 Predicting Exposure and Response to Safinamide in Parkinson's Disease (PD) Using Population Pharmacokinetic and Pharmacodynamic Modelling: M Campioni, S Krösser, M Thapar, S Hayes, E Gibiansky, V Lucini , R Anand
P19.04 Effects Of Safinamide As Add-On To L-Dopa On Symptom Severity And Aspects Of Daily Living In Patients With Mid- To Late-Stage Parkinson's Disease: J Szasz, R Borgohain, M Bhatt, S Rossetti, V Lucini , R Anand, for Study 016 investigators
P19.05 Rasagiline 1 mg/d Provides Benefits for Non-motor Symptoms in Patients with Early Parkinson's Disease: Results from the ADAGIO Study: W Poewe , R Hauser, A Lang
P19.06 Treatment With Rasagiline Provides Benefits in the Symptoms of Fatigue in Patients with Early Parkinson's Disease: F Stocchi
P19.07 Effect of Safinamide on Dyskinesia in Patients with Mid- to Late-Stage Parkinson's Disease: Data from a Post Hoc Analysis: M Bhatt, D Chirileanu, C Meshram, P Stanzione, E Forrest, V Lucini , for Study 016 Investigators
P19.08 An Open-Label Safety, Efficacy and Pharmacodynamic Investigation of SYN118 in Patients with Parkinson's Disease: N Al-Tawil, J Tedroff, C Carlström, Y Hallström, A Varrone, U Meya
P19.27 An Actively Transported Levodopa Prodrug (XP21279) in Patients with Parkinson's Disease: P LeWitt , A Ellenbogen, D Chen, R Lal, K McGuire, K Zomorodi, W Luo, F Huff

Clinical Science: Non-pharmacologic Therapies
P20.01 Long Term Impact of a Restorative Care Intervention for People with Parkinson's in the Community Setting: I Pretzer-Aboff , B Resnick, E Galik
P20.02 Clowning Improves Mobility In Parkinson's Disease: D Volpe , M Signorini, A Marchetto, V Bulgari, R McNeer, P MacDonald

Clinical Science: Rating Scales
P21.01 Measuring severity of impulse control disorders in Parkinson's disease using objective validated questionnaire: K Wu , M Politis, S Warsi, C Loane, S O'Sullivan, A Lees, P Piccini
P21.02 Nintendo™ Wii Remote Quantifies Finger Tapping in Parkinson's Disease: T Davis , A Chambers, J Yokely, J Fang
P21.03 Balance Assessment in Parkinson Disease: the BESTest and the Mini-BESTest : A Leddy , B Crowner, G Earhart
P21.04 Clinical Assessment of Motor Control in Parkinson Disease: Past, Present, and Future: F Melo , C Godinho, J Domingos, C Figueiredo, N Ferreira
P21.13 Validity of the new Test of upper limb Apraxia (TULIA) in Parkinson's disease: T Vanbellingen, F Baronti, R Müri, S Bohlhalter

Clinical Science: Behavioral Disorders
P22.01 Action and Object Naming in PSP (Progressive Supranuclear Palsy): R Sehgal , R Nehru  
P22.02 Premorbid Personality As Vulnerability Factor In The Development Of Impulse Control Disorders And Punding In Parkinson's Disease.: M Signorini , A Marchetto, C Volpato, D Volpe
P22.07 Patterns and Changes Over Time in Antipsychotic Prescribing in Parkinson's Disease : D Weintraub, D Weintraub , P Chen, R Ignacio, E Mamikonyan, H Kales

Clinical Science: Cognition
P23.01 Use of a Brief Computerized Test Battery to Identify Cognitive Changes in Parkinson's Disease: Kane, P Short, L Wulff, L Grattan, S Krutz, L Schulman, S Stern, A Cernich, S Reich, W Weiner
P23.02 [18F]FDG PET is a useful marker for posterior cortical dysfunction in Lewy body dementia: C Lee, J Kim , Y Kim, S Kim, J Kim
P23.03 Navigation in a virtual reality environment in Parkinson's: M Jog , S Angela, K Hrishikesh, K Garrett, V Vedran, K Mike, J Rachna
P23.04 Reliability and Utility of the ANAM-PD Computerized Test Battery for the Assessment of the Neuropsychological Features of Parkinson Disease: K Hawkins , D Jennings, K Marek, K Gilliland, A Vincent
P23.05 Cognitive deficits associated with Dopamine Transporter loss in the pre-motor subjects in the PARS Cohort: K Hawkins , D Jennings, K Marek, A Siderowf, M Stern, P PARS Study Investigators
P23.16 Significance of subjective memory complaints in non-demented patients with Parkinson's disease: P Lau , M Chong, W Lim, W Au, L Tan
P23.17 How do patients with newly diagnosed Parkinson's disease cope?: K Lode , K Bronnick, O Tysnes, J Larsen

Clinical Science: Sleep disorders/fatigue  
P24.01 Carotid intima-media thickness in patients with idiopathic restless legs syndrome: J Baik , S Han

Community & Quality of Life: Family care, caregiving, relationships
P25.01 Measuring existential, psychological and physical contributors to quality of life in Parkinson's disease using the McGill Quality of Life tool: M Jog, H Kumar, T Gofton
P25.02 Couples Living With Parkinson's Disease: Needs And Concerns At Advanced To End Stage: B Habermann, W Miller, S McLennon, H Chen, L Rafail, J Wojcieszek
P25.07 The Situation of Caregivers for Persons with Parkinson's Disease (PD): I Leiknes

Community & Quality of Life: Fitness, Wellness, Nutrition
P26.01 The Effect of Exercise on Self Reported Quality of Life: Efficacy of Exercise based on Age, Disease Duration and Gender: P Hatton, P Hatton , D Pan, R Dhall, M Coles
P26.02 Yoga Teacher Training for Students with Parkinson's Disease : R LeVerrier, T Rork DeAngelis, C Thomas

Community & Quality of Life: Alternative and complementary therapies/creativity, music and dance
P27.01 The Effects of a Music Accompanied Walking Program on Obstacle Crossing Behaviours in People with Parkinson's Disease: N de Bruin , J Doan, G Turnbull, S Bonfield, O Suchowersky, B Hu, L Brown 
P27.02 Rhythmic Auditory Stimulation (RAS) to Aid Gait in Patients with Parkinson Disease: A Myskja

Community & Quality of Life: Education: Lay and professional/health literacy
P28.01 Effect of PD Specific Education on Self-Reported Quality of Life: R Dhall, M Coles, P Hatton , D Pan, C Henderson
P28.02 Influencing Clinical Study Participation Through Peer to Peer Education: The Impact of a Multi-Disciplinary Training for People with Parkinson's : V Todaro, R Elliott
P28.03 United States Health Reform: How Patients with Parkinson's Disease View its Impact on their Medical Care: K Arney , T Davis
P28.04 Training multiple disciplines to work together in Parkinson's teams: Building a model interdisciplinary training program: R Hagestuen , G Gonzalez-Ramos, E Cohen

Community & Quality of Life: Disability and quality of life outcome measures  
P29.01 Determinants of quality of life improvement after DBS surgery.: R Dhall, M Coles, P Hatton , D Pan
P29.02 Current Peculiarities of Disability due to Parkinsonism in Ukraine: V Golyk , A Ipatov, O Zholob, O Moroz, H Rusina, D Bogouslavskyy
P29.03 Community walking: the perception of people with Parkinson Disease: R Lamont , M Morris, S Brauer
P29.04 Community based falls in people with PD: A prospective analysis of the first reported fall over 12 months: R Lamont , M Morris, J Watts, J McGinley, H Menz, R Iansek, A Murphy, E Waller, S Brauer
P29.13 Coping and Quality of Life in Parkinson's Disease: The Deep Brain Stimulation Effect: S Montel , A Bonnet, C Bungener
P29.14 Coping and Quality of Life as Related to Depression and Anxiety in Parkinson's Disease: S Montel , A Bonnet, C Bungener
P29.15 12-month Results From A Novel Test Battery Used In A Duodenal Levodopa Infusion Trial: J Westin , D Nyholm, A Johansson, M Memedi, M Dougherty, T Groth, S Pålhagen

Community & Quality of Life: Patient/caregiver/doctor community OR Healthcare teams
P30.01 A Cross-Cultural Lens Analysis of Health Care Practitioners' Perceptions of People with Parkinson's Disease: K Bogart, L Tickle-Degnen , H Ma
P30.02 Effect of facial masking on practitioner judgments of men and women with Parkinson's disease: A cross-cultural study : L Tickle-Degnen , L Zebrowitz, H Ma
P30.03 Direct Cost of Illness in Japanese Patients with Parkinson's Disease.: A Yoritaka-Saito , N Hattori
P30.09 Pharmacotherapy For Parkinson's Disease - Patients' Priorities: U. Wullner, G Fuchs, N Reketat, O Randerath, J Kassubek
P30.10 Coordination of care across multiple contact points in a comprehensive care model for People with Parkinson : R Gardiner , R Iansek, B Winkler

Community & Quality of Life: Palliative Care
P31.01 Defining and developing good Palliative Care for People Living with Parkinson's in Victoria, Australia, A work in progress: M Victor, V McConvey

Community & Quality of Life: Health services accesibility/underserved populations
P32.01 Telephone Based Nursing Management of Movement Disorders Patients-Maximizing Health Utility: L Hall, L Hall , M Jog
P32.02 Audit Cycle Of National Standards Related To Parkinson's Disease Care: I Singh , L Ebenezer, S Raha

Community & Quality of Life: Sexuality and intimacy
P33.01 Quality of Sexual Life (QoSL) in Parkinson Disease (PD): Perception of Patients and Spouses. : G Bronner , O Cohen, E Kozlova, N Molshatzki, H Strauss, S Hassin-Baer

Community & Quality of Life: Physical and Occupational therapy
P35.01 Can Occupational Therapy Have a Neuroprotective Effect on Functional Activities for Persons With Parkinson's Disease?: E Moyer
P35.02 An Exploration of Individuals' Perspectives on the Impact of Parkinson's Disease on Self-Care, Work and Leisure Activities: D Connolly, C Cassidy, E Ní Mhurchú, E Nolan
P35.03 Defining UK physiotherapy in Parkinson's disease: a modified Delphi survey: C Meek , C Sackley, C Clarke, S Shah
P35.04 Long-term Individual Fitness Enablement (LIFE) for Parkinson's disease: A feasibility study : C Meek , C Sackley, C Clarke, A Soundy, C Winward, P Esser, S Patel, H Dawes
P35.05 Unilateral auditory cueing to improve freezing during turning in Parkinson's disease: J Spildooren , S Vercruysse, K Desloovere, W Vandenberghe, J Vandenbossche, A Nieuwboer
P35.06 The Development Of Occupational Therapy Best Practice Guidelines For People With Parkinson's: A Aragon
P35.07 Comparative Study of Conventional Physiotherapy and Virtual Rehabilitation Using WII Fit for Improvement of Balance in Parkinson's Disease Patients.: A Loureiro , F Stori, R Chen, C Ribas, C Loureiro

Community & Quality of Life: Working, driving  
P37.01 Predictors of Disability Retirement in Newly Diagnosed PD: The Role of Motor Impairment and Neuropsychiatric Symptoms: H Dahle , G Alves, J Larsen, K Simonsen, O Tysnes, K Brønnick
P37.02 Parkinson's, Employment & Quality of Life: the Role of Job Control, Social Support and Self-Efficacy: L Cooper , S Knowles, S Moore


Wednesday - Late Breaking Abstracts

P36.01 Mitochondrial alterations in relation to synaptic pathology in Parkinson's disease: S Baloyannis , I Baloyannis
P36.03 Sleep Disorders in Patients with Early-Onset Parkinson`s Disease (EOPD) in a Specialty Hospital in Mexico. : H Bautista de la Cruz  
P36.04 Whole Exome and Targeted Re-Sequencing in Parkinson patients: S Biskup , D Boehm, T Scheurenbrand, C Schulte, T Gasser
P36.05 Pharmacokinetic Analysis Of Levodopa Titration Strategies With New Stalevo®75 And 125 Dose Strengths: K Ingman, T Naukkarinen, I Korpela, M Kuoppamäki, J Ellmén
P36.12 A Case-control Study of Restless Legs Syndrome in De Novo Previously Untreated Patients with Parkinson's Disease. Preliminary results.: S Calzetti, A Negrotti , M Angelini, E Marchesi, G Bonavina
P36.15 A Cost-effectiveness Analysis of Levodopa/Carbidopa Intestinal Gel (LCIG) Compared to Usual Care in Advanced Parkinson's Disase in the UK: S Morris, R Chaudhuri, L Findley, E Wood, A Bergman, M Schifflers , J Lowin, C Roeder
P36.16 The Economic Burden of Advanced Parkinson's Disease: An Analysis of a UK Patient Dataset: L Findley , S Morris, E Wood, A Bergman, M Schifflers, C Roeder
P36.23 Plasticity Induction by Pairing Subthalamic Nucleus Deep Brain Stimulation and Motor Cortical Transcranial Magnetic Stimulation in Parkinson's Disease: R Chen, K Udupa, N Bahl, C Gunraj, F Mazzella, E Moro, A Lozano, M Hodaie, A Lang
P36.27 FBXO7 mutations causing parkinsonian-pyramidal syndrome (PARK15) are associated with severely decreased levels of Fbxo7 protein: T Zhao , M Dekker, P Montagna, B Oostra, V Bonifati



Wednesday - Living with Parkinson's Abstracts

Educational and Awareness Raising Programs
LWP1.01 Partnerships between Movement Disorders Clinics Nurses and Parkinson Societies across Canada: Positive Impact on Service Delivery: L Lachance
LWP1.02 Conductive Education and Parkinson's Disease: M Heine
LWP1.04 Addressing the Needs of Newly Diagnosed PD Patients: Development of a Model Curriculum: D Cook , E Vierck
LWP1.05 Test your Parkinson's IQ: Parkinson Society Canada Awareness Campaign 2010: B Snelgrove , M Zacks
LWP1.06 The NeuroWriters' Guide to the Peripatetic Pursuit of Parkinson's Disease (PD): A Preview : G Muralidhar , P Wittekind, P Kell, K Huseman, J Wheeler, L Brooks, L Herman, J Citron, P Willocks, L Ashford, R Cummings

Government Advocacy/Campaigns/Public Policy
None

Living Healthier with PD 
LWP3.01 Partnering with a Community-Based Agency to Develop a Comprehensive Parkinson's Wellness Program: G Gonzalez Ramos , A Di Rocco, A Lemen, E Cohen, R Rossi
LWP3.02 The Layne Library, Using Social Networking to Improve the Lives of Parkinson's Patients: R Layne, A Gupta, C Bernard
LWP3.03 Faster, longer and stronger: A Kancilija Stanièiæ
LWP3.04 "Think Big" and "Feel Big" with Parkinson's Disease: Tamir, Pessach, O Lif Kimchi, O Lif Kimchi
LWP3.05 Beyond Medication: An Integral Rehabilitation Program for Patients with Parkinson´s Disease: A Costa, F Martins, J Marques, L Ferreira, W Kummer, H Moreira , P Alves, T Paranhos, M Verissimo, A Barbosa
LWP3.06 How The Power And Safety Of Water Helps People Cope With Parkinsons Disease: D Williams
LWP3.07 S.O.S -Electronic Passport for Parkinson's: D Raican

Influencing Reseach through Fundraising, Clinical Trials, Grassroots Campaigns
LWP4.01 Declaration of Clinical Rights and Responsibilities for People with Parkinson's: J Burns, L Herman, S Jedlinski, P Cohen, W DeCamp, S Planton, C Stephenson, P Willocks

General Topics  
LWP5.01 Rural Outreach Clinic in Rural Otago (New Zealand): P Ryan
LWP5.02 Quality Criteria from the Patient's Perspective: T van der Kolk, A Struiksma

---

THURSDAY - Scientific Abstracts

Basic Science: Etiology, genetics, epidemiology and toxicants
P01.10 ARHGEF7 (beta-Pix) the First Identified Guanine Nucleotide Exchange Factor for LRRK2: K Haebig , C Gloeckner, F Gillardon, M Ueffing, O Riess, S Biskup, M Bonin
P01.11 PARK9-Associated ATP13A2 Regulates Neuronal Integrity and Intracellular Cation Flux: D Ramonet , A Kosinska, L Glauser, D Moore
P01.12 A Cohort Study of Diet and Risk of Parkinson's Disease: K Sääksjärvi , P Knekt, A Lundqvist, M Heliövaara, S Männistö, H Rissanen, R Järvinen
P01.13 DNA Methylation In Lymphocytes And Brain Samples Of Parkinson's Disease Patients : O Kaut , I Schmitt, U Wüllner
P01.14 The Incidence of Progressive Supranuclear Palsy, Multiple System Atrophy and Vascular Parkinsonism in North-East Scotland (the PINE study).: R Caslake , J Gordon, C Harris, W Primrose, C Counsell
P01.15 Dementia With Lewy Bodies: A Role For Dementia And Parkinson's Disease Genes?: B Meeus , A Verstraeten, K Nuytemans, D Crosiers, S Engelborghs, M Van den Broeck, J Brys, M Mattheijssens, K Peeters, E Corsmit, E Elinck, B Pickut, P Cras, R Vandenberghe, P De Deyn, C Van Broeckhoven, J Theuns
P01.16 Relative significance of SCA2, SCA3 and SCA17 in Korean patients with parkinsonism: B Jeon, J Yun , W Lee, H Kim, J Kim, J Kim, S Kim, J Kim, S Park, Y Kim, S Kim, Y Kim
P01.17 Characterisation Of Lrrk2-Tubulin Interactions In Parkinson's Disease: D Berwick , B Law, R Sancho, K Harvey
P01.18 Personality Characteristics and Motor Skills attributed to Occupations in Parkinson's Disease: N Gatto, Y Bordelon, M Gatz, B Ritz
P01.30 Parkinsonism Incidence in North-East Scotland (the PINE study): The Incidence of Parkinson's Disease and Parkinonism.: R Caslake , C Harris, J Gordon, W Primrose, C Counsell
P01.31 Association of the glucocerebrosidase N370S allele and Parkinson's disease in two separate Chinese Han populations of mainland China: Y Xu , J Xi, F Hu, l Liu, X He, Z Liu, X Zou
P01.32 Lack of replication of association between polymorphism in the 3'UTR of the alpha-synuclein gene and Parkinson's disease in Chinese subjects: Y Xu, W Hu , F Hu, L Liu, L Yu, J Xi, X He, M Zhu, Z Liu

Basic Science: Cell death mechanisms, neuroprotection and trophic factors
P02.06 9-Methyl-ß-Carboline Inhibits Monoamine Oxidase Activity And Stimulates The Expression Of Growth Factors By Astrocytes: S Keller , H Reichmann, G Gille
P02.07 Stress is a Predisposing Factor for Parkinson's Disease in Males but not Females: D Dexter , R Allen, G Gillies, J Buckingham
P02.08 Glial Cell Derived Neurotrophic Factor Does not Provide Neuroprotection Against Alpha-synuclein-induced Toxicity in a Rat Model of Parkinson's Disease: M Decressac , A Ulusoy, D Kirik, A Bjorklund
P02.09 The Stress Protein RTP801 Is Required For Neuronal Death Induced by Alpha-Synuclein: O Levy , C Malagelada, L Greene
P02.10 Fluorescent Demonstration of Neurodegeneration via Gold Conjugate Immunolabelling InVitro.: O Ogundele , O Ghazal, O Jimoh, E Caxton-Martins
P02.19 14-3-3theta protects against neurotoxicity in PD models through the inhibition of the apoptotic factor Bax: T Yacoubian , S Slone
P02.20 Assessment of the Therapeutic Efficacy of Progranulin (PGRN) in a Sub-Chronic Animal Model of Parkinson's Disease : J VanKampen , D Kay
P02.21 Osteopontin Increases GDNF and BDNF Levels And Protects Against MPP+-Induced Tyrosine Hydroxylase Cell Loss In Primary Ventral Mesencephalic Culture. : L Broom , S Rose, P Jenner

Basic Science: Protein Misfolding and Handling
P03.03 14-3-3 Protein Can Act As A Molecular Chaperon That Inhibits -Synuclein Aggregation In Vitro : I Tessari, M Brucale, L Tosatto, F Munari, N Plotegher, D Kumar, S Capaldi, M Bisaglia, B Samorì, H Monaco, L Bubacco
P03.04 Proteasome Inhibition in Medaka Brain Induces the Features of Parkinson Disease: H Matsui, H Ito, Y Taniguchi, H Inoue, S Takeda, R Takahashi
P03.07 Development of alpha-synuclein as a potential molecular marker for Parkinson's disease: P Foulds, P Foulds , D Mann, J Mitchell, P Diggle, D Allsop

Basic Science: Mitochondria, Oxidative Stress, Inflammation and other Pathogeneses
P04.06 Role Of Pink1 In Parkinson's Disease And Mitochondrial Function: Pink1 Regulates Complex I Activity: V Morais , K Craessaerts, A Snellinx, L Overbergh, A Helbig, A Heck, W Mandemakers, W Wurst, B De Strooper
P04.07 Structural Characterization Of The Interaction Between Dj-1 And Dopamine-Derived Quinones: S Girotto, M Bellanda, M Sturlese, I Tessari, S Mammi, M Bisaglia , L Bubacco
P04.08 PARIS, a Parkin Substrate, Transcriptionally Represses PGC-1a Leading to Neurodegeneration in Parkinson's Disease: J Shin , H Ko, H Kang, Y Lee, O Pletinkova, J Troconso, J McCaffery, Y Lee, V Dawson, T Dawson
P04.09 Covalent Modifications of Superoxide Dismutase 2 By Dopamine Oxidation Products: E Belluzzi , M Bisaglia, P Polverino de Laureto, L Bubacco, M Beltramini
P04.10 HMGB-1 -An Inflammatory mediator in MPTP induced neuronal damage: K Sathe , S Mustafa, H Martin, K Tracey, P Teismann
P04.11 The differential proteome of the striatum of 6-OHDA lesioned rats: O Schmitt , G Lessner, S Haas, A Wree, K Michael, M Stefan, M Glocker
P04.02 Phosphorylation of HtrA2 by Cyclin Dependant Kinase 5: J Fitzgerald , H Plun-Favreau
P04.01 Pink1 Depletion Affects Mitochondrial Homeostasis : B Heeman, C Van den Haute, S Aelvoet, F Valsecchi, R Rodenburg, Z Debyser, W Koopman, P Willems, V Baekelandt
P04.19 Primary Complex I Defects Linked to AIF Deficiency Sensitizes Dopaminergic Neurons to Parkinsonian Neurotoxins: C Perier , J Bove, B Dehay, V Jackson-Lewis, P Rabinovitch, S Przedborski, M Vila
P04.20 Single-cell Redox Imaging Demonstrates a Peculiar Response of Dopaminergic Neurons to Oxidative Insults.: M Horowitz, C Milanese, R Di Maio, X Hu, L Montero, L Sanders, V Tapias, E Burton, J Greenamyre, P Mastroberardino

Basic Science: Pathology
P05.03 Validation of 4E-BP1 as a putative LRRK2 substrate: in vivo evidence.: R Bandopadhyay , B Phan, A Mamais, T Lashley, A Lees
P05.04 Characterization of Lewy Body Pathology in 12- and 16-year Old Intrastriatal Mesencephalic Grafts Surviving in a Patient with Parkinson's Disease: J Li, E Englund, H Widner, S Rehncrona, A Björklund, O Lindvall, P Brundin

Basic Science: Animal and Cellular Models
P06.05 The State of the Pre-synaptic Compartment Determines the Induction and the Maintenance of L-DOPA Induced Dyskinesia: A Ulusoy , G Sahin, D Kirik
P06.04 The Ginseng Extract, G115, is Neuroprotective in a Novel Progressive Rodent Model of PD : D Baranowski, H Robertson, C Shaw, D Kay, J VanKampen
P06.03 A PINK1 Mutant Zebrafish Model of Early Onset Parkinson's Disease: O Bandmann, L Flinn, H Mortiboys
P06.02 NRF2/SKN-1-Dependent GST-PI Inhibits Dopamine Neurodegeneration in Caenorhabditis Elegans Models of Parkinson's Disease and Manganism: R Nass , R Settivari, J LeVora
P06.19 Inhibition of Ras-GRF1 Signaling in the Striatum Reverts Motor Symptoms Associated to L-DOPA-induced Dyskinesia: S Fasano , E Bezard, A D'Antoni, M Indrigo, V Francardo, L Qin, S Doveró, M Cerovic, V Ghiglieri, V Bagetta, B Picconi, P Calabresi, M Cenci, R Brambilla
P06.20 Functional Interactions Between LRRK2 And Recessive Parkinson Disease Genes (Parkin, PINK1 And DJ-1) Mediate The Response To Mitochondrial Dysfunction: B Wolozin , M Guillily, H Li, A Ferree, N Pyenson, S Saha, J Collins
P06.21 Alterations in the Autophagy Pathway in Aged Horses with a Spontaneous a-Synucleinopathy and Dopaminergic Neurodegenerative Disease. : D McFarlane , K McDaniel, K Hill, M Cordero

Basic Science: Dopamine, receptors and other neurotransmitters
P08.02 Sequential changes in Behavioral and Biochemical parameters in rotenone induced Parkinson's disease model : Therapeutic potentials of Vitamin E : N Sharma , B Nehru

Basic Science: Neuropharmacology
P10.03 Cannabinoid Receptor Activation Reduced Dyskinesias and Tyrosine Hydroxylase Loss In Caudate-Putamem of 6-OHDA Lesioned Mice Treated with L-DOPA : M García-Gutiérrez , C Leiva, J Manzanares
P10.07 PYM50028 (Cogane™), a neurotrophic factor modulator, increases dopaminergic receptor density and BDNF and tyrosine hydroxylase levels in aged rats: Y Zhang, P Howson , Q Sun, Y Hu, Z Xia
P10.08 Protection of Dopaminergic Neurons by Tetrahydrocannabinol and Other Cannabinoids Against MPP+ and Glutamate Induced Damages in Mesencephalic Cultures: R Moldzio , C Krewenka, T Pacher, J Novak, W Rausch
P10.09 Nitric Oxide Synthase Inhibition Does Not Reduce Priming For Dyskinesia By L-DOPA In a Primate Model Of Parkinson's Disease: T Hirsch , A Hikima, M Jackson, K Tayarani-Binazir, R Fisher, S Rose, P Jenner

Basic Science: Electrophysiology
P11.03 Using Multiple Electrophysiological Techniques for the Differentiation of Parkinsonian Syndromes: K Fisher , H Lai, M Baker, D Burn, S Baker
P11.04 The Effect Of L-DOPA On The Firing Rate Of SNr Neurons In The Unilateral 6-OHDA Lesion Model Of Parkinson's Disease (PD): C Strauch , S Seeger-Armbruster, A von Ameln-Mayerhofer

Clinical Science: Symptoms, signs, clinical features and progression
P13.14 Extranigral extension of structural midbrain lesions overshadows parkinsonism: B Jeon, H Kim , J Yun, J Kim, Y Kim, G Erm, S Kim
P13.15 Effects of Turning and Backward Walking on Bilateral Coordination in Individuals with Parkinson Disease: D Peterson , M Plotnik, J Hausdorff, G Earhart
P13.16 Dorsal Rather Than Ventral Visual Pathways Discriminate Freezing Status In Parkinson's Disease: S Lord, S Lord , N Archibald, U Mosimann, L Rochester, D Burn
P13.17 Turning is altered in people with Parkinson's disease; differences can distinguish mild from moderate disease and freezers from non-freezers. : A Ashburn , C Kampshoff, M Burnett, E Stack, G Verheyden
P13.18 Lower limb Corticobasal Degeneration: K Noda , S Miura, Y Kaku, M Ayabe, H Aizawa, T Taniwaki
P13.19 Characteristics of Freezing of Gait in Community Dwelling People with Parkinson's Disease: M Danoudis , J McGinley, J Watts, H Menz, R Iansek, A Murphy, D Tan, M Morris
P13.20 Spinal Posture Is Altered In People With Parkinson's Disease And Can Be Measured With A Small And Simple Hand-held Device (SpinalMouse®): G Verheyden , L Tedesco Triccas, C Kampshoff, M Burnett, A Ashburn
P13.21 Detection of Gait Parameters, Bradykinesia and Falls in Patients with Parkinson's Disease by Using a Unique Triaxial Accelerometer: A Rodríguez-Molinero , D Pérez-Martínez, A Samà, P Sanz, M Calopa, C Gálvez, C Pérez-López, J Romagosa, A Català
P13.22 Freezing of Gait, Fear of Falling, and Quality of Life in People with Parkinson's Disease. : J McGinley , M Danoudis, H Menz, J Watts, R Iansek, A Murphy, M Morris
P13.23 Clinical Peculiarities of Manganese-Induced Encephalopathy: M Shalikashvili , N Lobjanidze, N Akiashvili, M Kapianidze, M Beridze, N Kvirkvelia, M Janelidze
P13.47 Impaired Digital Dexterity In Parkinson's Disease Is Associated With Higher-Order Praxis Function: T Vanbellingen, M Bellion, P Temperli, F Baronti, S Bohlhalter
P13.41 Dilated Virchow-Robin Midbrain Spaces in a Patient with Parkinsonian Syndrome and Familial Frontotemporal Dementia: G Tommasi , J Yelnik, F Alessandrini, G Puoti, G Fabrizi, G Zanusso, L Bertolasi, E Bardinet, S Monaco
P13.42 Gait freezing and speech disturbance in Parkinson's disease: correlation analyses using cueing effect: H Park, J Yoo, M Kwon, J Lee, S Lee, M Kim, S Chung
P13.43 A Computational Model of the Sensory Processing Deficits Observed During Hand Movements in Subjects with Parkinson's Disease: M Miller Koop , B Hill, H Bronte-Stewart
P13.44 Apparently Ipsilateral Parkinsonism in a Patient with Chronic Subdural Hematoma: T Ahn

Clinical Science: Non-motor Features
P14.06 Influence Of Comorbidity, Complications And Nonmotor Symptoms On Quality Of Life In Parkinson´s Disease: M Fischer , J Jörg, S Lange, S Isenmann  
P14.07 Intrajejunal Levodopa Infusion Therapy for Advanced PD : P Reddy , A Martin, P Martinez-Martin, P Odin, A Antonini, K Chaudhuri
P14.08 Body Fat Loss and HDL Cholesterol Improvement in Advanced Stages of Parkinson Disease: E Cassani , M Barichella, C Madio, R Cancello, E Cereda, C Pusani, G Pezzoli
P14.09 Body weight in Parkinson's disease: a systematic review and meta-analysis : M Van der Marck , H Dicke, Z Kentin, G Borm, B Bloem, S Overeem, M Munneke
P14.10 Self-reported non-motor symptoms in a cohort of 139 Parkinson's disease patients: D Crosiers , B Meeus, K Nuytemans, C Van Broeckhoven, J Theuns, P Cras
P14.22 Are there the differences of loss of dompaminergic neurons between idiopathic Parkinson disease with dementia and without dementia? A FP-CIT PET study: I Song , J Kim, H Kim, K Lee

Clinical Science: Biomarkers and Neuroimaging
P15.07 Functional Connectivity of Nucleus Ventralis Intermedius in Parkinson's Disease: Implications for Treatment: P Schweder , P Hansen, C Joint, A Green, T Aziz
P15.08 Myocardial Uptake of Meta-iodobenzylguanidine (MIBG) and Familial Parkinsonism: H Furuya , E Araki, H Arahata, H Kumazoe, N Fujii
P15.09 Serum urate and probability of dopaminergic deficit in early ¡®Parkinson disease¡¯: M Schwarzschild, K Marek, S Eberly, D Oakes, I Shoulson, D Jennings, J Seibyl, A Ascherio
P15.10 SYMPAR, a Web-Based Application Project for Electronic Storage and Integration of Genomic and Clinical Data for Parkinson's Disease Patients.: R Calligaris , M Banica, L Ferigo, T Cattaruzza, P Roncaglia, H Krmac, D Lazarevic, A Ceiner, N Pangher, G Pizzolato, S Gustincich
P15.11 Different roles of caudate nucleus and putamen in Parkinsonism -- analysis of TRODAT study: Y Lin , H Wang
P15.12 Susceptibility-Weighted Imaging of the Striatum in Multiple System Atrophy Compared to Parkinson's Disease: T M aeda , H T oyoshima, K Nagata, M Yamamoto
P15.23 Investigating Adenosine A2A receptor availability in Parkinson's disease patients with & without Levodopa induced Dyskinesias with [11C]SCH442416 PET.: A Ramlackhansingh , S Bose, I Ahmed, F Turkheimer, N Pavses, D Brooks
P15.20 Occipital hypoperfusion in Parkinson's disease by non-invasive measurement, arterial spine labering, using 3T MRI: Y Motoi, Y Motoi , K Kamagata, M Suzuki, K Shimoji, M Hori, T Hattori, J Nakanishi, Y Suzuki, S Sato, R Kuwatsuru, K Sasai, T Kambe, S Aoki, N Hattori

Clinical Science: Medical Therapy
P16.07 No correlation between COMT genotype and entacapone benefits in Parkinson's disease: B Jeon, J Kim , J Kim, J Kim, J Kim, S Chung, S Kim, M Kim, H Kim, K Choi, D Shin, Y Sung, K Lee, H Kim, J Cho, M Park, H Park, S Choi, K Park, H Lee, T Ahn, O Kwon, S Kim
P16.08 Knowledge of Parkinson's Disease among Physicians in Calabar, South-South Nigeria.: U Williams , S Opara, R Agbulu, V Umoh, D Otokpa
P16.09 Patients' Perspective on Parkinson's Disease Therapies – Results of a Large-scale Japanese Survey: K Fujimoto , N Hattori, T Kondo, M Murata
P16.10 Comparison of Direct Switch to Levodopa/Carbidopa/Entacapone in Levodopa/Benserazide-treated and Levodopa/Carbidopa-treated Patients: A Meta-analysis: D Brooks , M Leinonen, H Nissinen
P16.11 Post Marketing Surveillance Study To Assess The Safety Profile Of Tasmar® (Tolcapone) Under European Marketed Conditions.: D MacMahon, M Steiger , N Fletcher, A Lees, J Esquivel
P16.19 Effects of Apomorphine on Parkinsonian Tremor: N Cinar, S Sahin, S Karsidag

Clinical Science: Surgical Therapy
P17.04 Transduction of Dopamine Neurons by Adenoviral Vectors is Modulated by CAR Expression: Rationale for Tropism Modified Vectors in PD Gene Therapy: T Lewis , J Glasgow, A Glandon, D Curiel, D Standaert
P17.05 Dissociated Effects Of Left, Right And Bilateral Stimulation Of The Subthalamic Nucleus On Motor, Speech And Language Function In Parkinson's Disease: G Schulz , T Bradberry, L Hosey, S Stager, L Li-Ching, R Pawha, K Lyons, L Verhagen, A Braun
P17.06 Effects of Dorsal Versus Ventral Subthalamic Nucleus Deep Brain Stimulation on Gait in Parkinson Disease: M McNeely , S Tabbal, M Campbell, M Karimi, J Hartlein, H Lugar, T Hershey, F Revilla, J Perlmutter, G Earhart
P17.11 DURAL ARTERIOVENOUS FISTULA (DAVF) : Presenting As Progressive Parkinsonism And Cognitive Deficit.: M Di Ioia , S Bifolchetti, L Bonanni, F Ciccocioppo, M D'Amico, D Monaco, M Mantenuto, C Di Carmine, F La Rover, L Marchionno, V Onofrj, M Onofrj, A Thomas

Clinical Science: Complications of Therapy
P18.02 Serum vitamin B12 and folate levels in Parkinson´s disease patients treated with duodenal levodopa infusion: D Santos-García , M Macías, M Llaneza, M Grande, P Carpintero, R de la Fuente-Fernández

Clinical Science: Clinical Trials
P19.09 Physical fitness in patients with Parkinson's disease: A Speelman , J Groothuis, M van Nimwegen, M Hopman, B Bloem, M Munneke
P19.10 The Natural Progression of Clinical Symptoms In Early Parkinson's Disease: Results from the ADAGIO delayed-start study: O Rascol
P19.11 The use of apomorphine in the PD SURG trial: C Rick , J Daniels, S Patel, N Ives, S Gill, T Varma, C Jenkinson, N Quinn, A Williams, K Wheatley,
P19.12 Monitoring Treatment Fidelity in the ParkFit study, a multifaceted behavioral program to increase physical activity in Parkinson patients: M van Nimwegen , A Speelman, M Gerrits, B Bloem, M Munneke
P19.13 Rasagiline in Early Parkinson's Disease (PD): Additional Efficacy and Safety Results From the ADAGIO Delayed-Start Study: O Rascol , C Olanow
P19.14 Rationale and design of the IMPACT study: A cluster controlled trial to evaluate cost-effectiveness of multidisciplinary care in Parkinson's disease : M Van der Marck , B Bloem, W Mulleners, E Hoogerwaard, S Overeem, E Adang, G Borm, M Munneke
P19.15 Physical Activity in patients with Parkinson's disease: M van Nimwegen , A Speelman, E van Rossum, S Overeem, D Deeg, M van der Horst, G Borm, B Bloem, M Munneke
P19.23 Repetitive Transcranial Magnetic Stimulation using the H-Coil for Parkinson's Disease: O Cohen, O Cohen , S Hassin-Baer, R Amiaz, Z Nitsan, L Ephraty, I Avisar, H Strauss, E Kozlova, A Zangen
P19.24 Pharmacokinetic Modeling of PYM50028 (Cogane™) Predicts Once Daily Dosing Can Achieve Plasma Levels in PD Patients Associated with Preclinical Efficacy: C Brindley, P Howson, J Locker, C Ward
P19.25 Effects of Safinamide as Add-on to L-dopa on Motor and Depressive Symptoms in Patients with Mid- to Late-Stage Parkinson's Disease: R Borgohain, N Mehta, O Bajenaru, R Quatrale, V Lucini , R Anand, for Study 016 Investigators
P19.26 Effects of Droxidopa (Northera™ ) on 24 Hour Blood Pressure (BP) In Patients With Symptomatic Neurogenic Orthostatic Hypotension (NOH).: H Kaufmann , K Klos, R Hutchman, S Isaacson

Clinical Science: Non-pharmacologic Therapies
P20.03 An Evaluation of a Cognitive Behavioural Therapy Group to Encourage the Self Management of Parkinson's Disease. : C Johnson
P20.04 A Methodology to Improve Social Adjustment After Bilateral Subthalmic Nuclei (STN) Deep Brain Stimulation (DBS) in Parkinson's Disease (PD): M Meyer , E Spitz, S Montel, N Gospodaru, G Barroche, R Schwan, S Colnat-Coulbois

Clinical Science: Rating Scales
P21.05 Reliability and validity of the ambulatory self confidence questionnaire in people with Parkinson Disease: S Brauer , R Lamont, M Morris, M Woollacott
P21.06 Use of proxies to measure disability in persons with Parkinson's disease : M Van der Marck , B Post, L Laverman, B Bloem, M Munneke
P21.07 Relation between Hoehn and Yahr Staging Scale and Postural Behavior in Parkinson Disease: A Dynamic Posturography Study: C Godinho , F Melo, V Ferret-Sena, M Dias, A Calado, C Semedo, J Domingos, O Fernandes
P21.08 Expression of Psychotic Symptoms in Parkinson's disease as Assessed by the Scale for the Assessment of Positive Symptoms (SAPS): H Williams , D Bahr, P Peters, R Mills


Clinical Science: Behavioral Disorders
P22.03 Effect of Subthalamic Nucleus Deep Brain Stimulation on Medication-induced Behavioral Disorders in Patients with Parkinson's Disease: K Kashihara , T Imamura, T Agari
P22.06 Pathological Gambling in PD is reduced by Amantadine: A Thomas , L Bonanni, F Gambi, G Sepede, N Cera, S Bifolchetti, V Onofrj, M D'Amico, D Monaco, F Ciccocioppo, M Onofrj
P22.08 Old Age, Lower Education, and Activity of Daily Living are the Predictors of Cognitive impairment in Mongolian Patients with Parkinson's Disease. : B Tsedensodnom , U Dashdorj

Clinical Science: Cognition
P23.06 Dementia And Its Profile In A Care Of The Elderly Movement Disorder Clinic: S Raha , L Ebenezer
P23.07 Memory-guided Saccades, Cognitive Status and Dementia in Parkinson's Disease: C Graham, M MacAskill, J Dalrymple-Alford, L Livingston, T Pitcher, T Anderson 
P23.08 Impaired Development of Strategies is Associated with Apathy in Parkinson's disease.: S Varanese, S Varanese , B Perfetti, C Morrison, M Ghilardi, A Di Rocco
P23.09 Relationship Between Apathy And Cognitive Deficits In Parkinson's Disease Patients With Mild Cognitive Impairment: M Petrova , M Raycheva, L Traykov
P23.10 Profiling Memory Impairment in Parkinson's Disease.: F Di Cesare, C Di Carlo, G Radicati, F Stocchi , M Fioravanti
P23.18 Frontal Cognitive Functions Of Essential Tremor Patients: D Demýray , S Ertan, F Engÿn, M Kiziltan, S Özekmekçý, G Kziltan, H Apaydin, E Eker

Clinical Science: Sleep Disorders/Fatigue
None

Community & Quality of Life: Family care, Caregiving, and Relationships
P25.03 Quality of Life of People with Parkinson's Disease and their Caregivers: D Kelly , J McGinley, B Galna, J Watts, H Menz, R Iansek, A Murphy, M Morris
P25.04 A Comparison Study of Caregiver Burden in Family Members of Parkinson's Disease versus Alzheimer's Disease.: J Cho , J Lee, J Lee, H Shin, J Ahn
P25.08 Parkinson's and Dementia: How Dancing Helps Ethel to Move and be Happy.: M Le Messurier

Community & Quality of Life: Fitness, Wellness, and Nutrition
P26.03 Community Wellness Programs: A Model to Improve Quality of Life and Daily Function in People with Parkinson Disease: T Ellis , T DeAngelis, E Hoover, M Saint-Hilaire, C Thomas

Community & Quality of Life: Alternative and Complementary Therapies/Creativity, Music and Dance
P27.03 Short-Term Effects of a Community-Based Tango Program on Motor and Non-Motor Symptoms, Activities of Daily Living, and Motor Complications in PD: G Earhart, J Rotello, R Duncan
P27.05 Methodology Developed to Improve PD Patients' Quality of Life by Applying Theoretical Principles of Paradoxical Phenomenon in the Parkinson Workshop : J Dillon , M Bacigalupe, S Pujol

Community & Quality of Life: Education: Lay and Professional/Health Literacy
P28.05 The Role of Online Tools in Delivering Education About Parkinson's Disease to People with Parkinson's and Care Partners: C Evers, R Elliott
P28.06 Education of Health Professionals in Multidisciplinary Management of Parkinson's Disease : F Lindop
P28.07 Disease-Specific Training For Care Assistants: A Randomised Controlled Trial Comparing Two Approaches For Improving Understanding Of Parkinson's: H Gage, S Ting, C Chorley , J Kaye, K Bryan, P Williams, L Axelrod, P Trend, D Wade

Community & Quality of Life: Disability and quality of life outcome measures
P29.05 Balance, Gait Speed Flexibility, and Physical Activity Predict Walking Capacity in People with Parkinson Disease: M Ford , J Cavanugh, G Earhart, T Ellis, K Foreman, L Dibble
P29.06 Health Related Quality of Life in Moldavian Parkinson Disease Patients: G Pavlic , I Moldovanu, S Odobescu, L Rotaru, G Corcea
P29.07 Long-term Benefits of a Comprehensive Care Model for People with Parkinson (PwP): M Makoutonina , R Prof. Iansek, L Hardwick
P29.08 Relationships between gait hypokinesia and disability in community dwelling adults with Parkinson's disease: D Tan , S Soh, M Danoudis, J McGlinley, H Menz, R Iansek, A Murphy, M Morris
P29.16 An Analysis of Hope in Parkinson's Disease: M Giroux , M Glisky, S Farris
P29.17 Instrumental Activities of Daily Living Performance in Parkinson Disease Without Dementia: E Foster , J Watkins

Community & Quality of Life: Patient/caregiver/doctor community OR Healthcare Teams
P30.04 Improving Patient Care Through GP Online Education: M Dixon & Hennessy, M Dixon , T Hennessy
P30.05 Interdisciplinary Care In A Parkinson Disease Center: A Model For Patient Care, Education, Social Service and Community Outreach: D Tarsy , D Simon, L Shih, V VanderHorst, A Silver, E Gandelman, L Kapust, L Kraics, M Thall, M O'Connor, D Harrier, D Jefferson, C Wagner, J Piel, A Whitmill, J Matheson
P30.06 Cues To Meet Expectations's Patients From A Interprofessionnal Evaluation Program: C Lepage, C Lepage

Community & Quality of Life: Palliative Care
None

Community & Quality of Life: Health Services Accesibility/Underserved Populations
P32.03 Suspected Parkinson's: Referral and First Clinic Visit to the Specialist in the United Kingdom: G Drutyte, G Drutyte , K Breen, D Robertson, G Multi-professional Steering
P32.04 Mapping a Hospital Based Parkinson's Service Against National Guidelines with Recommendations on how Quality of Service can be Improved. : L Brown

Community & Quality of Life: Sexuality and intimacy
None

Community & Quality of Life: Working, driving
None

Community & Quality of Life: Speech therapy
P34.02 Quality Indicators For Speech-Language Therapy In Parkinson's Disease: J Kalf , M Munneke
P34.01 Guidelines For Speech-Language Therapy In Parkinson's Disease: J Kalf , B de Swart, B Bloem, M Munneke

Community & Quality of Life: Physical and Occupational therapy
P35.08 Clinical scales of balance and turning duration in Parkinson disease: F Rodrigues-de-Paula , L King, A Salarian, F Horak
P35.09 Electromyographic study of the sit-to-walk movement in individuals with and without Parkinson's disease: F Rodrigues-de-Paula , M Camargos, R Lana, L Teixeira-Salmela, L Oliveira Lima
P35.10 Kinetics and kinematics parameters of the sit-to-walk movement in individuals with Parkinson's disease: F Rodrigues-de-Paula , R Lana, M Camargos, L Teixeira-Salmela, L Oliveira Lima
P35.11 Muscular Strength in Individuals with Early Parkinson's Disease: L Oliveira Lima , F Rodrigues-de-Paula, L Teixeira-Salmela
P35.12 The OTiP Pilot: Design Of A Trial Evaluating The Feasibility Of A Large Scale RCT On The Effectiveness Of Occupational Therapy In Parkinson's Disease : I Sturkenboom, M Nijhuis-van der Sanden, B Bloem, G Borm, M Graff, M Munneke
P35.13 Guidelines for Occupational Therapy in Parkinson's Disease: I Sturkenboom, B Bloem, M Munneke
P35.20 Supporting Evidence-Based Physiotherapy In Parkinson's Disease: The Association Of Physiotherapy In Parkinson's Disease Europe (Appde): M Graziano , D Jone, A Nieuwboer, M Munneke, S Keus, M Hubert, F Lindop




Thursday - Late Breaking Abstracts

P36.06 Mapping of LRRK2 phosphorylation sites – the GTPase domain Roc represents a primary target for autophosphorylation: C Gloeckner , K Boldt, F von Zweydorf, S Helm, A Meixner, H Sarioglu, M Ueffing
P36.07 The Application of Multivariate Model-building to Derive Predictive Biomarker Signatures in Parkinson's Disease Patients: S Gunselman , T Woodford, D Bramwell, B Chase, M Tsintou, K Markopoulou
P36.08 Axonal Polyneuropathy during Duodenal Levodopa Teratment in a Woman with Idiopatic Parkinson Disease: G Gusmaroli , D Barbagli, M Ravagnani, M Mongiovetti, L Capone, R Tarletti, U Massazza, E Barbero
P36.02 Treatment with Duodenal L-dopa Infusion : D Barbagli , G Gusmaroli, M Ravagnani, M Mongiovetti, L Capone, R Tarletti, U Massazza, E Barbero
P36.09 The Montreal Cognitive Assessment (MoCA) and Korean Mini-Mental State Examination (K-MMSE) in Parkinson's disease: S Kim , E Chung
P36.10 Comparison of [18F]FDG-PET findings in PIB(+) Lewy body dementia, PIB(-) Lewy body dementia and Alzheimer disease: J Kim, J Kim, S Oh, S Kim, S You, D Aarsland, C Lee
P36.11 Long Term Program Of Social Theatre for the Management of Motor and Motor Symptoms of Parkinson's Disease: N Modugno, N Modugno , F Lena, I Kusch, M Fiorilli, G Mirabella
P36.13 Assessment of loneliness in patients with Parkinson's disease and their caregivers: M Oo , S Thompson
P36.14 Melanoma and Breast Cancer Among Patients with Parkinson Disease: A Population Based Cohort Study: K Rugbjerg , S Friis, C Funch Lassen, B Ritz, E Schernhammer, L Korbo, J Hansen, L Wermuth, A Bak Jylling, M Jensen, J Olsen




Thursday - Living with Parkinson's Abstracts

Educational and Awareness Raising Programs
LWP1.03 Communication, Cooperation, Community. The "triple C" rule to raise awareness on YOPD: F Capitanio  
LWP1.07 Blogging by People with Parkinson's Disease: An Assessment of Two "Motivational" Patient Blogs in Terms of Purpose, Positivity and Popularity: J Stamford, R Kuhn
LWP1.08 Working and Crossing National and Cultural Boundaries to Spread Parkinson's Awareness: F Capitanio , J Burns, C Martinez
LWP1.09 “POP-IN” A Rolling Educational Programme for Parkinson's Disease Patients and their Families: C Thompson , S Atkins, B Utting, K Amar
LWP1.10 Music and Parkinson's Disease: "My Life": G Griffith
LWP1.11 Simulation Based on an Unfolding Case Study “Living with Parkinson's Disease: An American Experience”: M McCormick

Government Advocacy/Campaigns/Public Policy
None

Living Healthier with PD
LWP3.08 Dream! Act! Live! Life After Diagnosis: How To Live Your Best Life Now!: T Bischoff
LWP3.09 How Team Parkinson helps PD patients Achieve a Better Quality of Life.: J Ball
LWP3.10 Every Victory Counts: A patient care program offering inspiration and self care support for living well with Parkinson's disease: M Giroux, S Farris, A Howard
LWP3.11 The Parkinson's Self Assessment Tool: H Matthews , J Ashton, D Heisters
LWP3.12 Parkinson's Stepping Forward Salsa and the Benefits of Dance: D Côté , N Tano, K Rowat, D Grimes
LWP3.13 Creating a Specialist Speech and Language Therapy Service for People with PD in East Dorset: Making a Difference: S Owens , H Reynolds, K Amar
LWP3.19 Examining the Potential of a Shared Education and Training Program to Increase the Psycho-Social Quality of Life in PWPs: L Morgan , V Todaro, C Hunter

Influencing Reseach through Fundraising, Clinical Trials, Grassroots Campaigns
LWP4.02 Patient Involvement in Parkinson's Research – 20 years of SPRING : F Hill , C Holme, J Telford

General Topics
LWP5.03 Reducing the Burden of Parkinson's Disease: M Emr , B Sieber
LWP5.04 From Car Park to Commisioning: J Looker, C Huston

---

FRIDAY - Scientific Abstracts

Basic Science: Etiology, Genetics, Epidemiology and Toxicants
P01.19 Sunlight Exposure and Parkinson's Disease in California: N Gatto, M Cockburn, J Bronstein, B Ritz
P01.20 Diabetes mellitus and risk of Parkinson's disease: Q Xu, Y Park, X Huang, D Umbach, A Hollenbeck, A Blair, A Schatzkin, H Chen
P01.21 Multivitamin Use and Risk of Parkinson's disease among Older Adults : Q Xu, Y Park, X Huang, A Hollenbeck, A Blair, A Schatzkin, H Chen
P01.22 Using Drug Purchase Data to Estimate the Occurrence of Parkinson's Disease in Israel, 1998-2008: O Chillag-Talmor , N Giladi, S Linn, T Gurevich, B El-Ad, B Silverman, N Friedman, C Peretz
P01.23 The Relationship Between Blood Levels of Heavy Metals and Parkinson's Disease in China.: X Tan , Y Luo
P01.24 Dietary characterizes of Chinese PD patients: food intake survey results: X Tan , Y Luo
P01.25 Analysis of Point Mutations and Single Nucleotide Polymorphisms Effects on Risk of Development of Parkinson's Disease in Russia: E Filatova , M Shadrina, P Slominsky, A Karabanov, S Illarioshkin, S Limborska
P01.26 Analysis of the PARK2 gene exon rearrangements and the SNCA gene multiplications in patients with Parkinson's disease from Russia: E Semenova , P Slominsky, G Bagyeva, S Illarioshkin, M Shadrina
P01.33 SNP rs7684318 of the a-synuclein Gene is Associated with Parkinson's Disease in Chinese Han Population: Y Xu , L Yu, P Xu, X He, F Hu, Z Lin, M Zhu, Z Liu, L He
P01.34 Pilot Study of Nosological Spectrum of Neurodegenerative Parkinsonism in Georgia: I Khatiashvili , M Megrelishvili, M Janelidze, N Lobjanidze
P01.35 Parkinsonian Syndrome After Carbon Monoxide Poisoning With Good Response On Dopaminergic Therapy: V Miletiæ , M Relja
P01.36 Total, LDL, and HDL Cholesterol and Parkinson's Disease in Men and Women : E O'Reilly , K Simon, X Gao, A Ascherio

Basic Science: Cell Death Mechanisms, Neuroprotection and Trophic Factors
P02.11 Phosphatase profile in Cassava (Manihot escculenta) induced neurotoxicity; Role in Neuronal degeneration.: O Ogundele , O Jimoh, O Ghazal, E Caxton-Martins
P02.12 Mode of Neuronal Cell Death in Potassium Hexacyanoferrate Induced Parkinson-Like Symptoms in Adult Wistar Rats.: O Ogundele , O Jimoh, O Ghazal, E Caxton-Martins
P02.13 Cannabinoids are neuroprotective in a human cell culture model of Parkinson's disease: C Carroll , M Zeissler, V Stone, C Hanemann, J Zajicek
P02.14 N-acetyl-L-cysteine Prevents Dopamine Toxicity in PC12 cells: Role of Toxic Quinones: A Maiti , M Bagh, S Jana, S Chakrabarti, N Saha, G Paul
P02.15 The roles of Pitx3 and microRNAs in the Differentiation of Embryonic Stem Cells to Dopamine Neurons: L Weidong , Y Dehua
P02.16 GDNF Rescues Injured DA Neurons but Fails to Reduce the á-synuclein-containing Protein Aggregation in UPS Impairment Induced Neurodegeneration Models: L Weidong , D Yuanlan, L Xuping
P02.22 Histone Deacetylase Inhibitor Exacerbates Hydrogen-Peroxide-Induced Cell Death In Neuroblastoma Cell Lines. : C Page , S Rose, P Jenner
P02.23 Potential Significance of Oxyresveratrol as Neuroprotective Agent in Different Experimental Models of Parkinson's Disease: R Chang , J Chao, Y Cheung, C Hung, M Wang

Basic Science: Protein Misfolding and Handling
P03.05 Alpha-synuclein is secreted, taken up by neighbouring cells and induces seeding of endogenous alpha-synuclein : A Bergström , P Kallunki, C Hansen, E Angot
P03.08 Regulation of LRRK2 kinase activity by GTP is indirect and requires upstream binding proteins: J Taymans , F Gao, A Beilina, E Lobbestael, V Bekelandt, M Cookson

Basic Science: Mitochondria, Oxidative Stress, Inflammation and Other Pathogeneses
P04.12 Ablation of Major Histocompatibility Complex II provides Neuroprotection in the MPTP Mouse Model of Parkinson's Disease.: H Martin , K Sathe, S Mustafa, J Forrester, P Teismann
P04.13 Dopamine Metabolism by Monoamine Oxidase is Connected to Oxidative Stress in the Rat Brain: Y Aluf , J Vaya, S Khatib, J Finberg
P04.14 Changes in Iron-regulatory Gene Expression Occur in Human Cell Culture Models of PD: C Carroll , M Zeissler, N Chadborn, K Gibson, G Williams, K Morrison, J Zajicek, C Hanemann
P04.15 Promyelocytic Leukaemia Protein Inclusion Bodies in Parkinsonian Astrocytes: J Evans , P Durrenberger, R Reynolds, E Grünblatt, D Dexter
P04.16 Suppression of MPTP-induced neurotoxicity in mice by NS-398, a selective cyclooxygenase (COX)-2 inhibitor: role of caspase-3 and NF-kB cascade: A Gupta , A Kumar, S Kulkarni
P04.21 Synuclein-Mediated Microglial Activation And Oxidative Stress In Parkinson's Disease: K Maguire-Zeiss , D Joseph, L Feng, J Trecki, H Federoff, E Yehling, T Mhyre
P04.22 Mitochondrial Alterations in Parkinson's Disease: S Baloyannis

Basic Science: Pathology
P05.05 Tissue Transglutaminase Locates to ER in Parkinson's Disease: A Novel Mechanism Linking Neuronal Stress to Protein Aggregation?: M Wilhelmus , R Verhaar, J Bol, C Jongenelen, G Andringa, P Cras, J Hoozemans, B Drukarch
P05.06 Parkinson's UK Tissue Bank: High Quality Human Brain, Spinal Cord and CSF samples Available for Parkinson's Research: D Dexter , D Gveric, R Reynolds, S Gentleman, L Middleton, F Roncaroli

Basic Science: Animal and Cellular Models
P06.11 Characterisation of Behavioural and Neurodegenerative Changes Induced by Intranigral 6-Hydroxydopamine Lesions in a Mouse Model of Parkinson's Disease: S Grealish , B Mattsson, P Draxler, A Björklund
P06.12 Characterization of Transgenic Mice Overexpressing Human Mutated a-Synuclein or with Mouse G2019S LRRK2.: M O'Neill , T Murray, J Cooper, N Buckner, E Browne, C Cella, K Knopp, C Evans, M Ward, J Poling, C Bruce, E Eberle, S Mitchell, K Merchant
P06.13 Inhibition Of The Prostaglandin E2 Receptor Subtype P1 Provides Neurorpotection In The Mptp-Model Of Parkinson's Disease.: S Mustafa, R Mounsey, K Sathe, H Martin, Y Hsieh, P Teismann
P06.14 Biochemical Characterization Of Full-Length Human Recombinant LRRK1 And LRRK2: L civiero, L Civiero , J Taymans, A Beilina, M Cookson, V Baekelandt, L Bubacco, E Greggio
P06.15 The Role of Norepinephrine Neurons in Motor Symptoms of Parkinson's Disease and Development of L-DOPA-induced Dyskinesia: E Shin , A Björklund, M Carta
P06.16 Motor Recovery after Retinal Pigment Epithelial (RPE) Cells Implantation in the Rat Model of Parkinson's Disease (PD): H Gambhir , S Vivekanandhan, V Goyal, R Mathur, M Behari
P06.01 Acute effects of spinal cord stimulation in large-scale brain circuits in a transgenic mouse Parkinson's model.: R Fuentes , K Dzirasa, M Nicolelis

Basic Science: Brain Physiology and Circuitry
None

Basic Science: Dopamine, Receptors and Other Neurotransmitters
P08.03 The Contribution of 123-I MIBG and 123 I-FP-CIT SPECT (DaTscan) Imaging in the Detection of Early Parkinson's Disease The Contribution of 123....: X Geronikola-Trapali , I Armeniakos, A Georgakopoulos, P Karabina, A Stefanoyannis, S Bakalis, V Lyra, P Zotou, G Labrakopoulos, A Prentakis, L Stefanis
P08.04 Regulation of AAV-mediated continuous DOPA delivery using destabilizing domains: T Bjorklund , E Ahlm Cederfjall, D Kirik

Basic Science: Neuropharmacology
P10.04 Protective Effect Of Flavonoids Against 3-Nitropropionic Acid Induced Cognitive Dysfunction, Glutathione And Mitochondrial Alterations In Rats: P Bansal , H Kalonia, A Kumar
P10.10 Substrate kinetics plasma membrane Na, K-ATPase in Parkinsons disease: M Ericjovicic , V Kostic, N Sternic, L Rakic
P10.11 Continuous Administration Of Rotigotine Enhances Wakefulness But May Deepen Sleep In 6-OHDA Lesioned Rats.: D Scheller , N Dürmüller, G Peyon, E Esneault, P Moser
P10.12 Delivering carbidopa subcutaneously enhances levodopa pharmacokinetics: a new strategy for controlling motor fluctuations: O Yacoby-Zeevi, S Oren, P LeWitt

Basic Science: Electrophysiology
P11.05 Time-frequency Analysis of Brain Electrical Activity in Early and Advanced Parkinson Patients by Wavelet Transform Method.: A Gabova , G Kuznetsova, V Gnezditski, M Korolyov, Y Obukhov
P11.02 Blink Reflex Excitability In Parkinson's Disease And Amyotrophic Lateral Sclerosis: J Gutierrez , G Lara, E Esteban, T Zaldivar, N Garofalo, H Hernández, O Hardiman

Clinical Science: Symptoms, Signs, Clinical Features and Progression
P13.24 Young Onset Parkinson's: Characteristic Movement Disorders and Profile of an Australian Sample: J Tan , J McGinley, M Danoudis, J Watts, H Menz, R Iansek, A Murphy, M Morris
P13.25 Does Peripheral Neuropathy Worsen Balance Performance & Functional Mobility in Persons with Parkinson Disease?: L Dibble , J Cavanaugh, G Earhart, T Ellis, M Ford, K Foreman
P13.26 Accumulation of Comorbidities Worsens Functional Mobility, Motor Deficits, and Quality of Life in Persons with Parkinson Disease: L Dibble , J Cavanaugh, G Earhart, T Ellis, M Ford, K Foreman
P13.27 Amplitude and duration of anticipatory postural adjustments are dependent on acceleration and remain unchanged in Parkinson's Disease: L Hall , S Brauer, P Hodges
P13.28 Association between Cancer and LRRK2 Mutations in Parkinson's Disease Patients : R Inzelberg , S Hassin-Baer, O Cohen, J Aharon-Peretz, I Schlesinger, R Gershoni, R Djaldetti, E Schechtman, E Friedman
P13.29 An Unexpected Clinical Progression In A Parkinson's Disease Patient. : S Jackson , R Sheridan
P13.30 PERFORM: A System For The Home Monitoring And Management Of Persons With Neurodegenerative Motor Disorders: R Greenlaw , S Konitsiotis, D Baga, P Bougia, M Pastor, M Pansera, D Fotiadis
P13.31 A Rare Coincidental Case Of Early Onset Parkinson's Disease And Multiple Sclerosis. : S Jackson , T Harrower
P13.32 Gait Variability In Parkinson's Disease: Influence Of Walking Speed And Medications: M Bryant, D Rintala, A Fernandez, A Charness, J Hou, E Lai, E Protas
P13.33 What Combination of Tests Best Identifies Fallers in People with Parkinson Disease?: G Earhart , J Cavanaugh, T Ellis, M Ford, K Foreman, L Dibble
P13.34 The 9 Hole Peg Test: What Does it Really Measure in People with Parkinson Disease?: G Earhart , J Cavanaugh, T Ellis, M Ford, K Foreman, L Dibble
P13.35 Diagnosing PSP-P in clinical practice- clues to diagnosis and distinction from Richardson syndrome and idiopathic Parkinson's disease : R Nehru, A Batla , S Puri
P13.36 The Parkinson's Progression Markers Initiative: A Prospective Biomarkers Study: T Sherer, S Chowdhury, M Frasier, J Eberling, B Ravina, A Siderowf, C Scherzer, D Jennings, C Tanner, K Kieburtz, A Ansbach, B Mollenhauer, J Seibyl, C Coffey, A Toga, L Shaw, J Trojanowski, K Marek
P13.37 Oculomotor and Visual Perceptual Changes Associated with Parkinson's Disease Without Dementia: A Zylstra , M Glisky, K Ballen
P13.46 Review and intervention of patients with Parkinson's disease by community pharmacist.: P Benson, P Cotton , C Miller
P13.45 Parkinson disease, clinic characteristics in a mexican population. Prospective observational study, preliminar report.: C León-Jiménez , J Martínez-Coronel, G Shobe-Lim, S Vega-Gaxiola, M García-Bravo, L Cortes-Sanabria

Clinical Science: Non-motor Features
P14.11 A community-based study of Parkinson's non-motor symptoms: K Breen , G Drutyte
P14.12 Poor Executive Function, Neuron Loss, and Gliosis in the Locus Coeruleus: The Honolulu-Asia Aging Study : H Petrovitch , R Abbott, G Ross, J Uyehara-Lock, L White
P14.13 Anhedonia In Parkinson's Disease: Analysis Using Snaith-Hamilton Pleasure Scale: S Miura , H Kida, K Noda, Y Kaku, K Nagasato, M Ayabe, H Aizawa, T Taniwaki
P14.14 The Prevalence and Frequency of Gastrointestinal Symptoms in Patients with Newly Diagnosed Parkinson's Disease: J Kim , H Sung, I Song, K Lee, H Kim
P14.15 Non-motor symptoms in Thai Parkinson's disease Patients: K Vongvaivanich , S Nidhinandana, P Sithinamsuwan P14.19 Frequency of Non-Motor Symptoms in Parkinson's Disease Patients : R Manso , M Sevillano
P14.18 Somatoform Disorders in Parkinson's Disease and Dementia with Lewy Bodies. : M Onofrj, L Manzoli, L Bonanni, F Gambi, V Onofrj, S Bifolchetti, A Thomas
P14.17 Autonomic Dysfunctions in Parkinsonian Disorders: J Kim , H Bae, S Cheon
P14.16 Restless Leg Syndrome on Various Stages of Parkinson's Disease (pilot study).: K Akhvlediani , I Khatiashvili, S Kasradze, M Kapianidze

Clinical Science: Biomarkers and Neuroimaging
P15.13 Putaminal Abnormality on 3T Magnetic Resonance Imaging in Early Parkinsonism Predominant Multiple System Atrophy: J Lee , J Yun, C Shin, H Kim, B Jeon
P15.14 Regional Cerebral Blood Flow in Parkinson's Disease: E Horiuchi, K Hasegawa , T Yokoyama
P15.15 Parkinson's Disease Markers in REM Sleep Behavior Disorder: M Schiess , A Hood, R Bick, V Ephron, R Castriotta, E Furr-Stimming, T Ellmore
P15.16 Ephedrone encephalopathy: Correlation Between Clinical Course and Hyperintensivity of the Basal Ganglia on the T1-weighted MRI Images: N Lobjanidze , I Khatiashvili, M Janelidze, E Melikidze, N Kvirkvelia, M Beridze, M Shalikashvili
P15.17 Identification Of Plasma Glycoproteins Unique To Diagnosis And Correlated With Severity Of Parkinson's Disease: C Pan , H Hwang, J Zhang, A Hancock, M Shi, K Chung, J Leverenz, C Zabetian, E Peskind, J Jankovic, J Quinn, D Galasko, J Zhang
P15.18 Olfactory Testing And Diffusion Tensor Imaging Of Olfactory Tract And Substantia Nigra In Early Parkinson's Disease.: H Robertson , T Rolheiser, H Fulton, K Good, R Leslie, J Fisk, J McKelvey, K Schoffer, N Khan, C Scherfler
P15.21 Cerebrospinal Fluid Alpha-synuclein Levels as a Biomarker for Lewy Body Disease: D Mann, P Foulds , D Allsop
P15.22 Identification and characterization of Parkinson's disease in asymptomatic patients: G Pasinetti
P15.19 Plasma uric acid correlates with iron accumulation in substantia nigra : M Pohja , H Antell, P Häkkinen, T Parviainen, T Annanmäki, V Poutanen, J Numminen, K Murros

Clinical Science: Medical Therapy
P16.12 Apomorphine Infusion in an Advanced Parkinson's Disease Patient with Prominent Tremor Refractory to Oral Treatment Strategies: D Aygun , L Gungor, M Onar, D Yazici
P16.13 H Pylori Eradication For Parkinson's Disease: K Rees, R Stowe, S Patel , N Ives, K Breen, C Clarke, Y Ben-Shlomo
P16.14 Anti-Hypertensive Drugs As Disease-Modifying Agents For Parkinson's Disease: Evidence From Observational Studies And Clinical Trials: K Rees, R Stowe, S Patel , N Ives, K Breen, Y Ben-Shlomo, C Clarke
P16.15 Non-Steroidal Anti-Inflammatory Drugs As Disease Modifying Agents For Parkinson's Disease: Evidence From Observational Studies: K Rees, R Stowe, S Patel, N Ives , K Breen, C Clarke, Y Ben-Shlomo
P16.16 Systematic Review Of Levodopa Dose Equivalency Reporting In Parkinson's Disease: C Tomlinson , R Stowe, S Patel, C Rick, R Gray, C Clarke
P16.17 Gastrointestinal Disorders in Patients with Parkinson's Disease (PD): A Double-Edged Sword: F Richy , A Gunn, L Makaroff, C Gervasoni, S Helmers
P16.18 Initial Diagnosis and Treatment Patterns in Parkinson's Disease: M Tarrants, M Lage , J Castelli-Haley

Clinical Science: Surgical Therapy
P17.07 Deep Brain Stimulation for Early Parkinson's Disease: C Kao, C Kao , M Remple, D Charles, J Neimat, P Konrad
P17.08 Effect of deep brain stimulation of the STN on novel metrics of habitual physical activity patterns in advanced Parkinson's disease.: L Rochester , S Chastin, K Baker, D Jones, D Burn
P17.12 Economic evaluation of deep brain stimulation: Results from the PDSURG Trial: E McIntosh
P17.13 Comparison of Microelectrode versus Magnetic Resonance Imaging Targeting in Parkinson´s Disease Patients Undergoing Pallidal Deep Brain Stimulation: V Evidente , K Ziemba, M Lyons

Clinical Science: Complications of Therapy
P18.03 Immunohistochemical Detection Of Fosb/Ģfosb-Like Proteins Maps Areas Of Maladaptive Neuroplasticity In The Post-Mortem Parkinsonian Brain: H Lindgren , S O'Sullivan, A Lees, M Cenci

Clinical Science: Clinical Trials
P19.16 Design of a randomized controlled trial evaluating the effectiveness of a multifaceted program to increase physical activity in Parkinson patients: A Speelman , M van Nimwegen, K Smulders, S Overeem, G Borm, F Backx, B Bloem, M Munneke
P19.17 Study of Intracerebroventricular Administration of sNN0031 (rhPDGF-BB) to Patients With Parkinson´s Disease (PD), Using an Implanted Pump System: G Paul , H Widner, S Pålhagen, S Rehncrona, G Lind, B Linderoth, H Bjartmarz, K Jansson, N Herne, O Zachrisson, A Haegerstrand, P Almqvist
P19.18 A Multicenter Randomized, Double-Blind, Placebo-Controlled Trial of Paroxetine and Venlafaxine Extended Release for Depression in Parkinson's Disease : I Richard , M McDermott, W McDonald
P19.19 Transcranial Magnetic Stimulation in Parkinsons Disease improvement in motor symptons and correlation with fMRI.: J Soto
P19.20 Systematic Overview of Randomised Trials of Physiotherapy in Parkinson's Disease: S Patel, C Tomlinson, R Stowe, C Meek, C Clarke, C Sackley, N Ives
P19.21 Should PD Treatment Be Started Immediately On Diagnosis Or Delayed Until Functional Disability Develops? Meta-Analysis Of Delayed-Start Design Trials: C Clarke , N Ives, S Patel, C Rick, K Wheatley, R Gray
P19.22 A large randomised assessment of the relative cost-effectiveness of different classes of drugs for Parkinson's disease (PD MED Trial): S Patel , V Cheed, N Ives, C Clarke, C Rick, K Wheatley, R Gray
P19.28 Camptocormia and Abnormal Axial Posture: Clinical, Fisiopathological Characterization and Therapy: F Pimazzoni , M Ferlisi, G Tommasi, A Fiaschi, L Bertolasi

Clinical Science: Non-pharmacologic Therapies
P20.05 The Effectiveness of Different Cueing Devices for People with Parkinson's disease and Gait Initiation Difficulties : P McCandless , B Evans, J Richards, J Selfe, A Churchill

Clinical Science: Rating Scales
P21.09 Patient Versus Informant Reporting of ICD Symptoms in Parkinson's Disease: Agreement and Validity: D Weintraub , K Papay, E Mamikonyan, A Siderowf, J Duda, M Stern
P21.10 Typical Physical Activity Levels in People with Parkinson Disease: Effect of Disease State, Gender and Age: T Ellis , J Cavanaugh, G Earhart, M Ford, K Foreman, L Dibble
P21.11 Which UPDRS Motor / Mobility Items Best Predict Quality of Life in People with Parkinson's Disease?: T Ellis , J Cavanaugh, G Earhart, M Ford, K Foreman, L Dibble
P21.12 Initial validation of a self administered version of the Freezing of Gait Questionnaire (FOGQsa): M Nilsson , K Wictorin, S Bladh, Å Högstedt, M Eliasson, C Toreld, J Reimer, P Hagell

Clinical Science: Behavioral Disorders
P22.04 Prevalence and Peculiarities of Neuropsychiatry in Not Treated Non-Demented Parkinson Disease : N Lobjanidze , M Janelidze, M Beridze, N Kvirkvelia, T Maisuradze, N Akiashvili
P22.05 Clinical characteristics of impulse control disorders in people with idiopathic Parkinson's disease: J Kim , M Kim, J Baik, S Koh

Clinical Science: Cognition
P23.11 How Well Can Screening Instruments Discriminate Among PD Patients with Normal Cognition, Mild Impairments, and Dementia?: G Watson , S Thomas, C Zabetian, B Gerton, H Kim, A Samii, A Schantz, J Leverenz
P23.12 Clinico- demographical correlations of dementia in pathologically confirmed PD. : M Selikhova , S O'Sullivan, A Guekht, T Revesz, A Lees
P23.13 Applause Sign and Cognitive Deficit in Parkinson Disease Patients: S Tomic , M Vladetic, A Cosic, S Butkovic-Soldo, S Misevic, A Soldo
P23.14 Gray Matter Atrophy and Severity of Cognitive Impairment in Parkinson's Disease: D Weintraub, D Weintraub , J Doshi, C Davatzikos, A Siderowf, J Duda, S Xie, C Clark
P23.15 Study about relationship between depression and cognitive impairment in Parkinson disease patients: D Pirscoveanu, D Pirscoveanu , C Zaharia, V Tudorica, F Trifan, D Matcau
P23.19 Old age, lower education, and activity of daily living are the predictors of cognitive impairment in Mongolian patients with Parkinson's disease.: K Baatar , B Tserensodnom

Clinical Science: Sleep Disorders/Fatigue
None

Community & Quality of Life: Family care, Caregiving, and Relationships
P25.05 Community administered of PD in XiangFan, Hubei, China : Y Luo , X Tan
P25.06 Elderly Couples in Transition: Their Experiences at the Moderate Stage of Parkinson's. : L Beaudet , F Ducharme

Community & Quality of Life: Fitness, Wellness, Nutrition
P26.04 Serum Cu Fe Mn Zn Levels and Parkinsons's diease: X Tan , Y Luo

Community & Quality of Life: Alternative and Complementary Therapies/Creativity, Music and Dance
None

Community & Quality of Life: Education: Lay and Professional/Health Literacy
P28.08 Learning About Parkinson's Disease (PD) Through Poetry And Pictures: D Jones , S Powell, T Taylor
P28.09 Information Seeking Behavior of People with Parkinson's and their Care Partners: P Wiener, R Elliott
P28.10 Measuring The Readability Of Online Patient Orientated Parkinson's Disease Information: P Fitzsimmons , B Michael, J Hulley, M Horner, G Scott

Community & Quality of Life: Disability and Quality of Life Outcome Measures
P29.09 Activity Levels in Parkinson Disease: Self-Assessment and Predictive Factors: J Rotello , G Earhart
P29.10 Relationships Between Participation, Quality of Life and Mobility in Individuals with Parkinson Disease: R Duncan , G Earhart
P29.11 Ten-meter Walking Time and Six-minute Walking Distance in Thai Non-Disabled Elderly: A Foongchomcheay
P29.12 What Features of Parkinson Disease Impact Disability and Quality of Life?: L Shulman , A Gruber-Baldini, K Anderson, B Robottom, P Fishman, S Reich, W Weiner
P29.18 Clinically Relevant Difference in Health-Related Quality of Life following 24-hour Transdermal Delivery of Rotigotine in Parkinson's Disease Patients: K Kulich , K Mueller
P29.19 Disability In Newly Diagnosed PD. Symptoms Associated With Reception Of Public Home Care Service: K Brønnick , G Alves, H Dahle, I Leiknes, O Tysnes, J Larsen

Community & Quality of Life: Patient/Caregiver/Doctor Community OR Healthcare Teams
P30.07 Moving Towards Patient Centered Healthcare for Patients with Parkinson's Disease in the Netherlands: M van der Eijk , M Faber, M Munneke, B Bloem
P30.08 Developing Northumbria Parkinson's Disease Information Service: A Hand , R Walker, K Greenwell, S Corbett, E Hulland, A Finlayson
P30.12 A Web Application For Follow-Up Of Results From A Mobile Device Test Battery For Parkinson's Disease Patients: M Memedi , J Westin, D Nyholm, M Dougherty, T Groth
P30.11 Role of Patient Support in Shaping Expectations and Decision Making with Deep Brain Stimulation (DBS) Surgery: O Klepitskaya, K Kelsall , V Graham, C McRae

Community & Quality of Life: Palliative Care
None

Community & Quality of Life: Health Services Accesibility/Underserved Populations
P32.05 Knowledge of Disease and Attitude Toward Treatment in Patients with Parkinson Disease: A Hospital-based Questionnaire Study : H Kim , J Kim, B Jeon, J Cho, J Yun, J Lee
P32.06 An Analysis of the Needs of Homebound Patients with Parkinson's Disease and their Caregivers in the Indian subcontinent - A Qualitative Study: M Barretto , B Singhal, J Lalkaka, P Wadia, S Devare
P32.07 A Parkinson's Review Clinic Within A Care Home Setting: P Edmonds, K Ullyart

Community & Quality of Life: Sexuality and Intimacy
None

Community & Quality of Life: Working, Driving
None

Community & Quality of Life: Speech Therapy
None

Community & Quality of Life: Physical and Occupational Therapy
P35.14 Effectiveness Of An Enhanced Multidisciplinary Community Based Group Program For Parkinson's Disease.: C Peters, M Currin, A Rogers , S Tyson, T Comans, S Healy, S McPhail, K Heathcote, S Brauer
P35.15 Assessment of Upper Limb Function in People with Parkinson's Disease: a Survey of Therapist Practice.: E Proud , K Miller, C Martin, M Morris
P35.16 Effects Of An Intensive Multitask Gait Training Program On Spatiotemporal Gait Parameters And Falls In Parkinson Disease: A Case Study: J Domingos , F Melo, C Godinho, A Castro-Caldas
P35.17 PD REHAB: Randomised Controlled Trial To Study The Effectiveness And Cost-Effectiveness Of Physiotherapy And Occupational Therapy For People With PD.: C Rick , C Clarke, C Sackley, M Walker, N Ives, S Patel, C Meek, G Yao, K Wheatley, C On behalf of the PD REHAB
P35.18 Feasibility of Abdominal Massage for the Alleviation of the Symptoms of Constipation in People with Parkinson's Disease: D McClurg, S Hagen, A Cunnington , L Paul
P35.19 An Evaluation of the Benefits of a Physiotherapist Accompanying the Occupational Therapist on Home Assessment Visits for Parkinson's Patients : A Cunnington , F Patterson
P35.21 The Impact of a 3- Month Group Physiotherapy Exercise Program in Functional Capacity of Patients with Parkinson Disease: D Aftosmidis , S Rosboglou, G Skamagki, A Sotirelis, D Pavlou, H Stefanis, S Bonstantzopoulou, Z Katsarou

Friday - Late Breaking Abstracts

P36.26 A Molecular Genetic Study of Parkinson's Disease in Zambia: E Yonova , M Atadzhanov, P Kelly, P Mwaba, B Kamanga, N Shawa, E Simons, G Breedveld, V Bonifati
P36.25 Impulse Control Disorders Subtypes in Parkinson's Disease: Clinical and PET Correlations : K Wu , M Politis, S O'Sullivan, S Bose, A Lees, P Piccini
P36.24 Medullo-spinal Circuitries Controlling Different Aspects of Gait: V VanderHorst , C Saper
P36.22 Indirect Comparison of Adverse Events and Dropout Rates for Early Parkinson's Disease (PD) Monotherapy Trials: Pramipexole, Ropinirole and Rasagiline: M Tarrants , F Zagmutt
P36.21 Somatosensory Processing in Parkinson's Disease: X Sun , T Hoque, C Gunraj, A Nelson, R Chen
P36.20 Umbelliferone and Esculetin Prevent 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Induced Nigrostriatal Neurotoxicity in C57BL/6J Mice : S Subramaniam , E Ellis
P36.19 The Neurobiology of Glucocerebrosidase Associated PD: Studies of Dopamine Synthesis and rCBF in GBA Mutation Carriers With and Without Parkinsonism: O Goker-Alpan, J Masdeu, P Kohn, G Lopez, D Eisenberg, C Groden, M Chalfin, A Ianni, K Berman, E Sidransky
P36.18 Vascular Endothelial Growth Factor-B186 Improves Motor Behavior In Vivo in a Rat Model of Parkinson's Disease: S Sherman , T Falk, S Zhang, X Yue
P36.17 Astrocyte-Dependent Protection by Inosine and Urate in a Cellular Model of Parkinson's Disease: S Cipriani, C Desjardins, T Burdett, Y Xu, K Xu, M Schwarzschild

Friday - Living with Parkinson's Abstracts

Educational and Awareness Raising Programs
LWP1.12 Facing the Future with Parkinson's: M Dixon
LWP1.13 The Grassroots Effort to Make the PD Tulip the National Symbol for Parkinson's Awareness in the United States: J Burns
LWP1.14 Parkinson's Outreach. Hope for Tomorrow. Help for Today.: I Robledo
LWP1.15 A Picture Can Make a Movement: P Zikos, S Berri, D Zouroudis, Y Papatriantafylou, K Papageorgiou
LWP1.16 Parkinson Partners: Coordinate Local Resources for Best Care: D Sutherland , D Sutherland

Government Advocacy/Campaigns/Public Policy
LWP2.01 Life with Parkinson's Awareness Campaign: S Lindvall , L Graham, K Browne
LWP2.02 Awareness of the Need for More Focused Research into Parkinson's Disease: S Lindvall , K Skoog
www.parkinsonsmovement.org -- A Hub for the Parkinson's Community: J Stamford , & the CPT Patient Advisory Gp
LWP2.03 www.parkinsonsmovement.org - A Hub for the Parkinson's Community: J Stamford, The Cure Parkinson's Trust

Living Healthier with PD
LWP3.14 European Parkinson's Disease Association (EPDA) Multilingual Website on Coping Strategies. Tricks Created by People with Parkinson's Disease.: M Graziano
LWP3.15 Painting with Parkinsons: Art as a therapy for Parkinson's : A Atkin, S Knowles, N Aimers, C Watson
LWP3.16 Sleep Self Management Project - Scotland : A Lynall
LWP3.17 Achieving the Impossible Together: H Young , E Dumitru, A Hernandez
LWP3.18 Parkinson Wellness Recovery Network (PWR!NET™). A model for delivering early and continuous access to neuroplasticity-principled exercise programming : B Farley, K Stepan, M Urquhart, S Christenson, M Nelson

Influencing Reseach through Fundraising, Clinical Trials, Grassroots Campaigns
None

General Topics
LWP5.05 Learning from Online Discussions about Parkinson's Disease Amongst People with Parkinson's and their Carers: A Verhaeghe, L Elleboudt
LWP5.06 A Qualitative Assessment of the Educational and Support Needs of People Living with Parkinson's Disease : S Lindvall , L Graham, E O'Brien, U Davis